
<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:fb="http://www.facebook.com/2008/fbml" xmlns:og="http://opengraphprotocol.org/schema/">
	<head><title>
	Here's What You Need to Know About Inovio Pharmaceuticals' First-Quarter Earnings
</title><meta http-equiv="Content-Type" content="text/html;charset=utf-8" /><meta property="fb:app_id" content="50808187550" />
	<meta http-equiv="imagetoolbar" content="no" />
	
	
	<link rel="image_src" href="http://g.foolcdn.com/art/facebook/FBdefault.png" />
   	
	
	<link rel="alternate" type="application/rss+xml" href="http://www.fool.com/feeds/index.aspx?id=foolwatch&format=rss2" />
    <link href="https://plus.google.com/100085898295463832129" rel="publisher"/>
	
	
	<link rel="canonical" href="http://www.fool.com/investing/general/2014/05/12/heres-what-you-need-to-know-about-inovio-pharmaceu.aspx" />

    
    
     <meta name='parsely-page' content='{
  "title": "Here\u0027s What You Need to Know About Inovio Pharmaceuticals\u0027 First-Quarter Earnings",
  "link": "http://www.fool.com/investing/general/2014/05/12/heres-what-you-need-to-know-about-inovio-pharmaceu.aspx",
  "image_url": "",
  "type": "post",
  "post_id": "7a4818fa-d9c0-11e3-aee8-0050569d4be0",
  "pub_date": "2014-05-12T17:30:00Z",
  "section": "Health Care",
  "author": "George Budwell"
}' />
    


        
<script type="text/javascript">
    window.analytics = window.analytics || [], window.analytics.methods = ["identify", "group", "track", "page", "pageview", "alias", "ready", "on", "once", "off", "trackLink", "trackForm", "trackClick", "trackSubmit"], window.analytics.factory = function (t) { return function () { var a = Array.prototype.slice.call(arguments); return a.unshift(t), window.analytics.push(a), window.analytics } }; for (var i = 0; i < window.analytics.methods.length; i++) { var key = window.analytics.methods[i]; window.analytics[key] = window.analytics.factory(key) } window.analytics.load = function (t) { if (!document.getElementById("analytics-js")) { var a = document.createElement("script"); a.type = "text/javascript", a.id = "analytics-js", a.async = !0, a.src = ("https:" === document.location.protocol ? "https://" : "http://") + "cdn.segment.io/analytics.js/v1/" + t + "/analytics.min.js"; var n = document.getElementsByTagName("script")[0]; n.parentNode.insertBefore(a, n) } }, window.analytics.SNIPPET_VERSION = "2.0.9",
    window.analytics.load("ul1430c8wv");
    window.analytics.page();
</script>

<link href="http://s.foolcdn.com/common/css/fool.css?v=83336a" rel="stylesheet" type="text/css" media="all" /><link href="http://s.foolcdn.com/common/css/Bridge.css?v=83336a" rel="stylesheet" type="text/css" media="all" />
	<link href="http://s.foolcdn.com/common/css/Usmf.css?v=83336a" rel="stylesheet" type="text/css" media="all" />
	
	
	
	<link href="http://s.foolcdn.com/common/css/globalTickerHover.css?v=83336a" rel="stylesheet" type="text/css" media="all" />
	<link href="http://s.foolcdn.com/css/predictive-search-results.css?v=83336a" rel="stylesheet" type="text/css" media="all" />
	
	<link href="http://s.foolcdn.com/css/articlepage.css?v=83336a" rel="stylesheet" type="text/css" media="all" />
	<link href="http://s.foolcdn.com/css/Modules/mom.css?v=83336a" rel="stylesheet" type="text/css" media="all" />
	<link href="http://s.foolcdn.com/css/main/todaysMarket.css?v=83336a" rel="stylesheet" type="text/css" media="all" />



			<script type='text/javascript'>
			var isUserNameCreated = false;
			var isLoggedIn = false;
			var hasUserName = true;
			var isRegistered = false;
			</script><script src="http://j.foolcdn.com/common/js/prototype_fool.min.js?v=83336a" type="text/javascript"></script>
			<script type="text/javascript">
			    var googletag = googletag || {};
			    googletag.cmd = googletag.cmd || [];
			    (function () {
			        var gads = document.createElement("script");
			        gads.async = true;
			        gads.type = "text/javascript";
			        var useSSL = "https:" == document.location.protocol;
			        gads.src = (useSSL ? "https:" : "http:") + "//www.googletagservices.com/tag/js/gpt.js";
			        var node = document.getElementsByTagName("script")[0];
			        node.parentNode.insertBefore(gads, node);
			    })();
            </script>
		
    <script src="//g.foolcdn.com/js/lib/raven.min.js"></script>
    <script>
        Raven.config('https://123828d5ad6c4615bd046ca90a689428@app.getsentry.com/18188', {
            whitelistUrls: ['fool.com/common/js/marketing/', 'foolcdn.com/common/js/marketing/', 'googletagmanager.com']
        }).install();
    </script>
    <script language="javascript" type="text/javascript">
        dfp_email = '';
    </script>
 	<script src="http://j.foolcdn.com/common/js/fx_usmf.min.js?v=83336a" type="text/javascript"></script>
	<!--[if IE 6]>
	<script src="http://j.foolcdn.com/common/js/DD_belatedPNG_0.0.8a.min.js" type="text/javascript"></script>
	<![endif]-->
	
	<script src="http://j.foolcdn.com/js/www_expando.min.js?v=83336a" type="text/javascript"></script>
	
	<script src="http://j.foolcdn.com/js/article_recommendations.min.js?v=83336a" type="text/javascript"></script>
	<script type="text/javascript">Article.prepare();</script>
	

    <script src="http://h.foolcdn.com/tmfstatic/js/vendor/jquery-1.7.2.min.js"></script>
    <script type="text/javascript">
        jQuery.noConflict();
    </script>
    <script src="http://s3.amazonaws.com/foolstatic/leadspend_validation.js" async></script>

	
	
	<!-- Start Google Analytics -->
	<script type="text/javascript">
		var _gaq = _gaq || [];
		_gaq.push(['_setAccount', 'UA-3262475-1']);
		_gaq.push(['_setDomainName', 'fool.com']);
		_gaq.push(['_trackPageview']);

		(function() {
			var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
			ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
			var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
		})();
	</script>
	<!-- End Google Analytics -->


<meta name="title" content="Here's What You Need to Know About Inovio Pharmaceuticals' First-Quarter Earnings" /><meta name="headline" content="Here's What You Need to Know About Inovio Pharmaceuticals' First-Quarter Earnings" /><meta name="STORY_UID" content="7a4818fa-d9c0-11e3-aee8-0050569d4be0" /><meta name="author" content="George Budwell" /><meta name="articletype" content="Investing" /><meta name="collection" content="Investing" /><meta name="date" content="2014-05-12T13:30:00-05:00" /><meta name="promo" content="A Foolish take on Inovio's first-quarter earnings report." /><meta name="description" content="A Foolish take on Inovio's first-quarter earnings report.  - George Budwell - Health Care" /><meta name="bureau" content="health-care" /><meta name="gsa_date" content="2014-05-12" /><meta name="gsa_date" content="2014-05-12" /></head>
	
	<body id="ctl01_ctl00_ctl00_ctl00_ctl00_ctl00_cphContent_Body" class="hlp Default collectionInvesting">
	    <script src="http://j.foolcdn.com/common/js/infotron.min.js?v=83336a" type="text/javascript"></script>        

	    

<script>
    dataLayer = [];
</script>
<!-- Google Tag Manager -->
<noscript>
    <iframe src="//www.googletagmanager.com/ns.html?id=GTM-HQ4K"
        height="0" width="0" style="display: none; visibility: hidden"></iframe>
</noscript>
<script>(function (w, d, s, l, i) {
    w[l] = w[l] || []; w[l].push({
        'gtm.start':
        new Date().getTime(), event: 'gtm.js'
    }); var f = d.getElementsByTagName(s)[0],
    j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
    '//www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
})(window, document, 'script', 'dataLayer', 'GTM-HQ4K');</script>
<!-- End Google Tag Manager -->

	    

<script type="text/javascript">
    (function (c, a) {
        window.mixpanel = a; var b, d, h, e; b = c.createElement("script");
        b.type = "text/javascript"; b.async = !0; b.src = ("https:" === c.location.protocol ? "https:" : "http:") +
        '//g.foolcdn.com/js/lib/mixpanel-2.2.min.js'; d = c.getElementsByTagName("script")[0];
        d.parentNode.insertBefore(b, d); a._i = []; a.init = function (b, c, f) {
            function d(a, b) {
                var c = b.split("."); 2 == c.length && (a = a[c[0]], b = c[1]); a[b] = function () {
                    a.push([b].concat(
                    Array.prototype.slice.call(arguments, 0)))
                }
            } var g = a; "undefined" !== typeof f ? g = a[f] = [] :
            f = "mixpanel"; g.people = g.people || []; h = ['disable', 'track', 'track_pageview', 'track_links',
            'track_forms', 'register', 'register_once', 'unregister', 'identify', 'alias', 'name_tag', 'set_config',
            'people.set', 'people.set_once', 'people.increment', 'people.track_charge', 'people.append'];
            for (e = 0; e < h.length; e++) d(g, h[e]); a._i.push([b, c, f])
        }; a.__SV = 1.2;
    })(document, window.mixpanel || []);
    
    mixpanel.init("9659875b92ba8fa639ba476aedbb73b9");
    mixpanel.set_config({
        track_pageview: false
    });
</script>


		
		
	<div id="header" class="navCellA">
			
				
		   

<!--This is DeliveryTemplates\Common\TopHatCommon.xslt--><div id="tophat" class="clearfix">
  <div id="tophatWrap">
	<div id="navigation" class="clearfix">
		<ul id="site-nav" class="site-nav-hide">
        <li class="countryIcon countryUSIcon"><a class="qs-source-iflsittph0000001 select" href="http://www.fool.com/">
					Fool.com
				</a></li>
        <li class="countryIcon countryGBIcon"><a class="qs-source-iflsittph0000001" href="http://www.fool.co.uk/">
					Fool.co.uk
				</a></li>
        <li class="countryIcon countryAUIcon"><a class="qs-source-iflsittph0000001" href="http://www.fool.com.au/">
					Fool.com.au
				</a></li>
        <li class="countryIcon countryCAIcon"><a class="qs-source-iflsittph0000001" href="http://www.fool.ca/">
					Fool.ca
				</a></li>
        <li class="countryIcon countrySGIcon"><a class="qs-source-iflsittph0000001" href="http://www.fool.sg">
					Fool.sg
				</a></li>
      </ul>
		<span id="quips">The World's Greatest Investing Community</span>
	</div>
	<div id="userTools">
		<span id="welcome">Welcome!</span>
		<ul id="premium" class="dropMenu">
        <li class="topLevel"><a aria-haspopup="true" href="javascript:void(0);" class="qsAdd qs-source-ipesittph0000001"><span><span>Premium Advice</span></span></a><ul id="premium-list">
            <li class="info subhead"><strong>My Services</strong></li>
            <li class="info">None</li>
            <li class="info subhead"><strong>Other Services</strong></li>
            <li><a class="qsAdd qs-source-ipesittph0000002" href="http://newsletters.fool.com/1255/">Fool One</a></li>
            <li><a class="qsAdd qs-source-ipesittph0000002" href="http://newsletters.fool.com/1008/">Hidden Gems</a></li>
            <li><a class="qsAdd qs-source-ipesittph0000002" href="http://newsletters.fool.com/1048/">Income Investor</a></li>
            <li><a class="qsAdd qs-source-ipesittph0000002" href="http://newsletters.fool.com/1066/">Inside Value</a></li>
            <li><a class="qsAdd qs-source-ipesittph0000002" href="http://newsletters.fool.com/1451/">MDP Deep Value</a></li>
            <li><a class="qsAdd qs-source-idpsithat0000002" href="http://newsletters.fool.com/30/">Million Dollar Portfolio</a></li>
            <li><a class="qsAdd qs-source-ipesittph0000002" href="http://newsletters.fool.com/50/">Motley Fool Options</a></li>
            <li><a class="qsAdd qs-source-ipesittph0000002" href="http://newsletters.fool.com/1228/">Motley Fool Pro</a></li>
            <li><a class="qsAdd qs-source-ipesittph0000002" href="http://newsletters.fool.com/1069/">Rule Breakers</a></li>
            <li><a class="qsAdd qs-source-ipesittph0000002" href="http://newsletters.fool.com/1062/">Rule Your Retirement</a></li>
            <li><a class="qsAdd qs-source-ipesittph0000002" href="http://newsletters.fool.com/52/">Special Ops</a></li>
            <li><a class="qsAdd qs-source-ipesittph0000002" href="http://newsletters.fool.com/18/">Stock Advisor</a></li>
            <li><a class="qsAdd qs-source-ipesittph0000002 last" href="http://newsletters.fool.com/1502/">Supernova</a></li>
          </ul>
        </li>
      </ul>
			
		
		<span id="Help"><a class="qsAdd qs-source-ihesittph0000001" href="/help/index.htm">Help</a></span>
		<span id="join"><a class="qsAdd qs-source-ijnsittph0000001" href="/landing/tmf/secure/registration.aspx">Join Now</a></span>
		<span>or</span>
		<span id="login"><a class="qsAdd qs-source-ilgsittph0000001" href="https://www.fool.com/secure/login.aspx">Login</a></span>
	</div>
</div><script type="text/javascript">Fool.Util.PseudoClass.addClassOnTap("#tophatWrap ul.dropMenu li.topLevel", "showSubMenu");</script></div><div id="topnav"><div class="grid">
  <!--DO NOT REMOVE THIS TOPNAV COMMENT!-->
  <div id="logo"><a class="qsAdd qs-source-illsitima0000001" href="http://www.fool.com/">The Motley Fool
			</a></div>
  <form id="searchForm" method="get" action="/search/solr.aspx"><fieldset id="search"><input type="hidden" name="exchange-input" id="top_exchange_input" /><input autocomplete="off" class="query" value="Enter Keywords or Ticker" type="text" name="q" maxlength="100" /><input type="hidden" name="source" value="ignsittn0000001" /><input id="commandSearch" class="btn doSearch" type="submit" /></fieldset></form>
  <div id="menu" class="grid clearfix"><div class="column span-25"><ul class="clearfix">
    <li class="qsAdd qs-source-iflsittph0000001"><a href="http://www.fool.com/" class="qsAdd qs-source-iflsittph0000001"><span>Home</span></a>
      <ul>
        <li class="qsAdd qs-source-ifltnvsnv0000001 foolwatch"><a href="/foolwatch/foolwatch.aspx" class="qsAdd qs-source-ifltnvsnv0000001 foolwatch">All Fool Headlines</a></li>
        
				<li class="qsAdd qs-source-ifltnvsnv0000001"><a href="http://military.fool.com/" class="qsAdd qs-source-ifltnvsnv0000001">Fool Military</a></li>
				<li class="last qsAdd qs-source-ifltnvsnv0000001"><a href="/press/about.htm" class="last qsAdd qs-source-ifltnvsnv0000001">About The Motley Fool</a></li>
      </ul>
    </li>
    <li class="qsAdd qs-source-ipesittph0000001"><a href="http://my.fool.com/" class="qsAdd qs-source-ipesittph0000001"><span>My Fool</span></a>
      <ul>
        <li class="qsAdd qs-source-ipesitlnk0000001"><a href="https://my.fool.com/Profile" class="qsAdd qs-source-ipesitlnk0000001">My Profile</a></li>
				<li class="qsAdd qs-source-ipesitlnk0000001"><a href="/myarticles" class="qsAdd qs-source-ipesitlnk0000001">My Articles</a></li>
        <li class="qsAdd qs-source-ipesitlnk0000001"><a href="http://my.fool.com/watchlist" class="qsAdd qs-source-ipesitlnk0000001">My Watchlist</a></li>
        <li class="qsAdd qs-source-ipesitlnk0000001 premium"><a href="http://newsletters.fool.com/MyScorecard/MyScorecardRedirect.aspx" class="qsAdd qs-source-ipesitlnk0000001 premium">My Scorecard</a></li>
        <li class="qsAdd qs-source-ipesitlnk0000001"><a href="http://boards.fool.com/FavoriteBoards.asp?" class="qsAdd qs-source-ipesitlnk0000001">My Boards</a></li>
        <li class="qsAdd qs-source-ipesitlnk0000001"><a href="http://caps.fool.com/MyPlayer.aspx" class="qsAdd qs-source-ipesitlnk0000001">My CAPS</a></li>
        <li class="qsAdd qs-source-ipesitlnk0000001"><a href="http://my.fool.com/#my-reports" class="qsAdd qs-source-ipesitlnk0000001">My Reports</a></li>
        <li class="last qsAdd qs-source-ipesitlnk0000001"><a href="https://www.fool.com/Account/Index.aspx" class="last qsAdd qs-source-ipesitlnk0000001">My Settings</a></li>
      </ul>
    </li>
    <li class="qsAdd qs-source-ifltnvpnv0000001"><a href="/how-to-invest/index.aspx" class="qsAdd qs-source-ifltnvpnv0000001"><span>How To Invest</span></a>
      <ul>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="/how-to-invest/thirteen-steps/index.aspx" class="qsAdd qs-source-ifltnvsnv0000001">13 Steps</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="/how-to-invest/broker/index.aspx" class="qsAdd qs-source-ifltnvsnv0000001">Find a Broker</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="http://wiki.fool.com/" class="qsAdd qs-source-ifltnvsnv0000001">Investing Wiki</a></li>
        <li class=" last qsAdd qs-source-ifltnvsnv0000001"><a href="/how-to-invest/personal-finance/index.aspx" class=" last qsAdd qs-source-ifltnvsnv0000001">Personal Finance</a></li>
      </ul>
    </li>
    <li class="qsAdd qs-source-ifltnvpnv0000001 on"><a href="/investing/index.aspx" class="qsAdd qs-source-ifltnvpnv0000001"><span>Investing Commentary</span></a>
      <ul>
        <li class="qsAdd qs-source-ifltnvpnv0000001"><a href="/investing/basics/index.aspx" class="qsAdd qs-source-ifltnvpnv0000001">Basics</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="/investing/etf/index.aspx" class="qsAdd qs-source-ifltnvsnv0000001">ETFs</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="/investing/options/options-a-foolish-introduction.aspx" class="qsAdd qs-source-ifltnvsnv0000001">Options</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="/investing/small-cap/index.aspx" class="qsAdd qs-source-ifltnvsnv0000001">Small-Cap</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="/investing/dividends-income/index.aspx" class="qsAdd qs-source-ifltnvsnv0000001">Dividends &amp; Income</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="/investing/high-growth/index.aspx" class="qsAdd qs-source-ifltnvsnv0000001">High Growth</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="/investing/value/index.aspx" class="qsAdd qs-source-ifltnvsnv0000001">Value</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="/mutualfunds/mutualfunds.htm" class="qsAdd qs-source-ifltnvsnv0000001">Mutual Funds</a></li>
        <li class="last qsAdd qs-source-ifltnvsnv0000001"><a href="/investing/international/index.aspx" class="last qsAdd qs-source-ifltnvsnv0000001">International</a></li>
      </ul>
    </li>
    <li class="capsTab qsAdd qs-source-ifltnvpnv0000001"><a href="http://caps.fool.com/index.aspx" class="capsTab qsAdd qs-source-ifltnvpnv0000001"><span>CAPS Community</span></a>
      <ul>
        <li class="capsHome qsAdd qs-source-icasitlnk0000006"><a href="http://caps.fool.com/" class="capsHome qsAdd qs-source-icasitlnk0000006">CAPS Home</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="http://caps.fool.com/" class="qsAdd qs-source-ifltnvsnv0000001">CAPS Home</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="http://caps.fool.com/MyPlayer.aspx" class="qsAdd qs-source-ifltnvsnv0000001">My CAPS</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="http://caps.fool.com/TickerRankings.aspx?filter=7&amp;sortcol=38&amp;sortdir=1" class="qsAdd qs-source-ifltnvsnv0000001">Stocks</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="http://caps.fool.com/Screener.aspx" class="qsAdd qs-source-ifltnvsnv0000001">Screener</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="http://caps.fool.com/PlayerRankings.aspx?filter=20&amp;sortcol=5&amp;sortdir=1" class="qsAdd qs-source-ifltnvsnv0000001">Players</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="http://caps.fool.com/Blogs/index.aspx" class="qsAdd qs-source-ifltnvsnv0000001">Blogs</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="http://caps.fool.com/Stats.aspx" class="qsAdd qs-source-ifltnvsnv0000001">Top Tens</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="http://caps.fool.com/TagRankings.aspx" class="qsAdd qs-source-ifltnvsnv0000001">Tags</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="http://caps.fool.com/Contests.aspx" class="qsAdd qs-source-ifltnvsnv0000001">Contests</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="http://caps.fool.com/FeedBack.aspx" class="qsAdd qs-source-ifltnvsnv0000001">Contact Us</a></li>
        <li class="last qsAdd qs-source-ifltnvsnv0000001"><a href="http://caps.fool.com/Help.aspx" class="last qsAdd qs-source-ifltnvsnv0000001">Help</a></li>
      </ul>
    </li>
    <li class="qsAdd qs-source-ifltnvpnv0000001"><a href="/retirement/index.aspx" class="qsAdd qs-source-ifltnvpnv0000001"><span>Retirement</span></a>
      <ul>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="/retirement/general/how-to-retire-in-style.aspx" class="qsAdd qs-source-ifltnvsnv0000001">13 Retirement Steps</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="/retirement/ira/index.aspx" class="qsAdd qs-source-ifltnvsnv0000001">IRAs</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="/retirement/401k/401kintro-is-your-retirement-plan-foolish.aspx" class="qsAdd qs-source-ifltnvsnv0000001">401(k)s, Etc.</a></li>
        <li class="last qsAdd qs-source-ifltnvsnv0000001"><a href="/retirement/assetallocation/introduction-to-asset-allocation.aspx" class="last qsAdd qs-source-ifltnvsnv0000001">Asset Allocation</a></li>
      </ul>
    </li>
    <li class="qsAdd qs-source-ifltnvpnv0000001"><a href="http://boards.fool.com/" class="qsAdd qs-source-ifltnvpnv0000001"><span>Boards</span></a>
      <ul>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="http://boards.fool.com/BestOf.asp" class="qsAdd qs-source-ifltnvsnv0000001">Best Of</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="http://boards.fool.com/favoriteboards.asp" class="qsAdd qs-source-ifltnvsnv0000001">Favorites &amp; Replies</a></li>
        <li class="qsAdd qs-source-ifltnvsnv0000001"><a href="http://boards.fool.com/EditFavoriteBoards.asp" class="qsAdd qs-source-ifltnvsnv0000001">Customize</a></li>
        <li class="last qsAdd qs-source-ifltnvsnv0000001"><a href="http://boards.fool.com/request.asp" class="last qsAdd qs-source-ifltnvsnv0000001">Start a New Board</a></li>
      </ul>
    </li>
    <li class="premium qsAdd qs-source-ipesittph0000001"><a href="/shop/newsletters/index.aspx" class="premium qsAdd qs-source-ipesittph0000001"><span>Fool Store</span></a>
      <ul>
        <li class="qsAdd qs-source-ipesitlnk0000001"><a href="http://newsletters.fool.com/18/index.aspx" class="qsAdd qs-source-ipesitlnk0000001">Stock Advisor</a></li>
        <li class="qsAdd qs-source-ipesitlnk0000001"><a href="http://newsletters.fool.com/04/index.aspx" class="qsAdd qs-source-ipesitlnk0000001">Hidden Gems</a></li>
        <li class="qsAdd qs-source-ipesitlnk0000001"><a href="http://newsletters.fool.com/15/index.aspx" class="qsAdd qs-source-ipesitlnk0000001">Rule Breakers</a></li>
        <li class="qsAdd qs-source-ipesitlnk0000001"><a href="http://newsletters.fool.com/30/index.aspx" class="qsAdd qs-source-ipesitlnk0000001">Million Dollar Portfolio</a></li>
        <li class="qsAdd qs-source-ipesitlnk0000001"><a href="http://newsletters.fool.com/1228/index.aspx" class="qsAdd qs-source-ipesitlnk0000001">Motley Fool PRO</a></li>
        <li class="last qsAdd qs-source-ipesitlnk0000001"><a href="http://app.fool.com/" class="last qsAdd qs-source-ipesitlnk0000001">Motley Fool Mobile</a></li>
      </ul>
    </li>
  </ul></div></div>
  <img width="0" height="0" class="vs-tracking-px" src="http://www.fool.com/tracking/vs/vs_track.gif?_rnd=2079876684&amp;actual_url=http%3a%2f%2fwww.fool.com%2finvesting%2fgeneral%2f2014%2f05%2f12%2fheres-what-you-need-to-know-about-inovio-pharmaceu.aspx&amp;articletype=collection548&amp;author=George+Budwell&amp;authortype=author&amp;bureau=Health+Care&amp;CellID=1%2c0%2c0%2c1%2c0%2c0%2c0%2c0&amp;cntSaverlayLogicView=AlwaysTrue&amp;cntSliderLogicView=ShowUserSliderCriteria&amp;headline=Here's+What+You+Need+to+Know+About+Inovio+Pharmaceuticals'+First-Quarter+Earnings&amp;log=1&amp;lvPromoLeaderboard=DoesntOwnFoolOneOrFoolOnePlus&amp;newsitetest=0&amp;referrer=http%3a%2f%2fnone%2f&amp;segment=default&amp;site=usmf.inv.investing&amp;storytype=Article&amp;TestID=YourMyMom%3a001%2cmvtSlider%3a01%2cprmoCSS%3a01%2cfeaturedArticlesTest%3a01%2ctickleDesign%3a001%2cticklePersist%3a001%2calreadyEcappedTest%3a001%2cmvtSaverlay%3a01&amp;uid=0&amp;url=http%3a%2f%2fwww.fool.com%2finvesting%2fgeneral%2f2014%2f05%2f12%2fheres-what-you-need-to-know-about-inovio-pharmaceu.aspx&amp;usmfRedirectCriteria=AlwaysTrue&amp;zone=articles" />
  
</div></div><script type="text/javascript">	var topNav = new Usmf.Tabs('menu'); topNav.insertSubnavElement('foolwatch', 'Motley Fool Funds', 'You are leaving Fool.com, operated by The Motley Fool, LLC.  Would you like to continue to FoolFunds.com, operated by Motley Fool Asset Management, LLC?', 'http://www.foolfunds.com'); new Fool.Util.SearchBox('searchForm');</script>
	</div>








		
	<div id="mid">
		<div class="grid">
			
	    <div id="flash">
		    
            
    
        <div id="promoAndLeaderboard" class="clearfix">
            <div class="leaderboard ad-728x90">
                <script type='text/javascript'>   var googletag = googletag || {};   googletag.cmd = googletag.cmd || [];   googletag.cmd.push(function() {googletag.pubads().setTargeting('sub','default');googletag.pubads().setTargeting('port','default');googletag.pubads().setTargeting('trades','default');googletag.pubads().setTargeting('reg','false');googletag.pubads().setTargeting('uid','0');googletag.pubads().setTargeting('etfticker','false');googletag.pubads().setTargeting('ret','default');googletag.pubads().setTargeting('mgr','default');googletag.pubads().setTargeting('funds','default');googletag.pubads().setTargeting('goldticker','false');googletag.pubads().setTargeting('bureau','health-care');googletag.pubads().setTargeting('ord_aband','default');googletag.pubads().setTargeting('series','default');googletag.pubads().setTargeting('buckettarget','default');googletag.pubads().setTargeting('swap','false');googletag.pubads().setTargeting('sessionCount','1');googletag.pubads().setTargeting('tenOrMoreSessions','false');googletag.pubads().setTargeting('type','269');googletag.pubads().setTargeting('adtags','growth,health-care,pharma,tech');googletag.pubads().setTargeting('tickers','INO,RHHBY,NVAX');   });</script><div id="div-gpt-ad-728x90-0"></div><script type="text/javascript">var pitcherAds = pitcherAds || PitcherAds();pitcherAds.get({placement: "leaderboard",divId: "div-gpt-ad-728x90-0",site: "usmf.inv.investing",zone: "articles",width: 728,height: 90,pos: "top",position: "0",seg: "default",tile: "1",sub: "default",port: "default",trades: "default",reg: "false",uid: "0",etfticker: "false",ret: "default",mgr: "default",funds: "default",goldticker: "false",bureau: "health-care",ord_aband: "default",series: "default",buckettarget: "default",swap: "false",sessionCount: "1",tenOrMoreSessions: "false",type: "269",adtags: "growth,health-care,pharma,tech",tickers: "INO,RHHBY,NVAX",src: ""});</script>
            </div>
            <div class="promo">
                <script language="JavaScript" type="text/javascript" src="http://ad.doubleclick.net/adj/usmf.inv.investing/articles;pos=;seg=default;src=;sz=237x90;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=2;ord=62663609?"></script><noscript><a href="http://ad.doubleclick.net/jump/usmf.inv.investing/articles;pos=;seg=default;src=;sz=237x90;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=2;ord=62663609?" rel="nofollow" target="_blank"><img src="http://ad.doubleclick.net/ad/usmf.inv.investing/articles;pos=;seg=default;src=;sz=237x90;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=2;ord=62663609?" border="0" alt=""></a></noscript>
            </div>
        </div>
	

    

		    
		    
	    </div>

	    <div id="layout" class="bigBox round clearfix">
				
					
		    
		    
	
	
	<div id="primary" class="column collection548">
	    
           <!-- AddThis Javascript -->
		    <script type="text/javascript" charset="utf-8">
		        // On window resize, adjust left position of toolbar to keep it within 20px of the content
		        // If it can't fit with 20px on either side, hide it and show the horizontal buttons
    		    Event.observe(window, "resize", hideShowToolboxes);

    		    Event.observe(window, "scroll", function () {
    		        var leftPos = Element.viewportOffset($('primary')).left - 105 + 'px';
    		        if ($('vertical_toolbox').visible()) {
    		            if (Element.viewportOffset($('primary')).top <= 10) {
    		                $('vertical_toolbox').setStyle({ position: 'fixed', top: '10px', left: leftPos });
    		            } else {
    		                $('vertical_toolbox').setStyle({ top: '0', left: '-85px', position: 'absolute' });
    		            }
    		        }
    		    });

    		    function hideShowToolboxes() {
    		        var width = document.viewport.getWidth();

    		        if (width <= document.minimumWidth) {
    		            hideVertical();
    		            showHorizontal();
    		        } else {
    		            showVertical();
    		            hideHorizontal();
    		        }
    		    }
    		    document.observe("dom:loaded", function () {
    		        $('mid').select('div.grid').each(function (div) { div.setStyle({ overflow: 'visible' }) });

    		        document.minimumWidth = 1150;
    		        if (document.viewport.getWidth() <= document.minimumWidth) {
    		            $('vertical_toolbox').hide();
    		            $('horizontal_toolbox').show();
    		        }
    		    });

    		    function showHorizontal() {
    		        if ($('horizontal_toolbox').visible() != true) {
    		            $('horizontal_toolbox').show();
    		        }
    		    }
    		    function hideVertical(argument) {
    		        $('vertical_toolbox').hide();
    		    }
    		    function hideHorizontal(argument) {
    		        $('horizontal_toolbox').hide();
    		    }
    		    function showVertical() {
    		        $('vertical_toolbox').show();
    		    }

    		</script>   


			<script type="text/javascript">   
				// My Articles Article Bookmarking
			    Fool.onContent(function() {
			        $(document).on("click", ".savethis", function(event, element){
			            
			            event.preventDefault();
			            var url = '/myarticles/save';
			            var pars = '';
			            pars += "headline=" + "Here's What You Need to Know About Inovio Pharmaceuticals' First-Quarter Earnings";
			            pars += '&item=' + 'http://www.fool.com/investing/general/2014/05/12/heres-what-you-need-to-know-about-inovio-pharmaceu.aspx';

			            var myAjax = new Ajax.Request(
			                url, 
			                {
			                    method: 'post', 
			                    parameters: pars, 
			                    onCreate: createResponse.bind(element),
			                    onComplete: successResponse.bind(element),
			                    onFailure: errorResponse
			                });
			        });
			    });

			    function createResponse() 
			    {
			        $(this).update("Saving Article...");
			        $(this).writeAttribute({"class": "saving"});
			    }

			    function successResponse()
			    {                       
			        $(this).writeAttribute({
			            "href": "/myarticles",
			            "class": "saved"
			        });

			        // Remove and insert view link after 2 seconds
			        var timer;
			        timer = setTimeout(function() 
			        {  
			            console.log(this);	
			            $(this).update('View My Articles')		
			        }.bind(this), 2000);
  					
			    }

			    function errorResponse()
			    {
			        // Do something if web service not working
			        console.log("Something went wrong!");
			    }
			</script>			



		    <!-- AddThis HORIZONTAL Buttons BEGIN -->
		    <div class="shareLinks clearfix addthis_toolbox"  id="horizontal_toolbox" style="display:none;">
				    <a class="addthis_button_facebook_like" fb:like:layout="button_count"></a>
				    <a class="addthis_button_tweet" tw:via="themotleyfool"></a>
				    <a class="addthis_button_email email_bg">Email</a>
				    <a class="addthis_button_print print_bg">Print</a>
                    <a class="addthis_counter addthis_pill_style"></a>
				    <!--<a class="addthis_button_google_plusone" g:plusone:size="medium"></a>-->
		    </div>

            <div class="printLogo">
                <img src="http://g.fool.com/art/foollogo/horizontaltmf.gif" alt="The Motley Fool"/>
            </div>
		
		<div id="content" class="hentry cms" itemscope itemtype="http://schema.org/Article">

			
			<!--googleon:all-->
			
			<!-- surphace start -->
			
			   <div id="recModule">
			        
			        
	<div class="recommendCtl">
		<div class="recWrap" id="numRecsWrapper" 
			title="3 members have recommended this article">
			<p>Recs</p>
			<h3>
				<span>
					3
				</span>
			</h3>
		</div>
		
			<div>
				<input type="submit" class="button" value="Rec This" 
					onclick="Recommendations.RecommendIt('0','2952688','Post', this);return false;" />
			</div>
		
	</div>

		        </div>
		        
		        



        <ul id="toolBox">
	        
	        
	        
	        
	        
	        
        </ul>



		    <h1 class="xlHeader">Here's What You Need to Know About Inovio Pharmaceuticals' First-Quarter Earnings</h1>

		    
	                

			
			<p class="articleMeta">
				<span class="vcard byline">By
				
					<a class="qsAdd qs-source-iapsitlnk0000002" href="http://my.fool.com/profile/gbudwell/info.aspx"><span itemprop="author" content="George Budwell">George Budwell</span></a> <meta itemprop="contributor" content="7472" />
				
				|
				<a class="qsAdd qs-source-iapsitlnk0000003" href="/author/7472/index.aspx">More Articles</a>
				</span> 
				

				<br />
				<span class="dateline">May 12, 2014</span>
				|
				<span class="comments"><a href="#commentsBoxAnchor">Comments (4)
				</a></span>
			</p>

			<div class="entry-content">
		       
				

				
				
					
						

				<p>Clinical-stage, synthetic-vaccine maker <strong>Inovio Pharmaceuticals</strong>  (<span class="ticker">NYSEMKT: <a data-id="215712" class="qsAdd qs-source-isssitthv0000001" href="http://caps.fool.com/Ticker/INO.aspx">INO</a></span>&nbsp;<a class="addToWatchListIcon qsAdd qs-source-iwlsitbut0000010" title="Add INO to My Watchlist" href="http://my.fool.com/watchlist/add?ticker=INO">&nbsp;</a>)  posted first-quarter earnings this morning and gave a number of clinical updates for its growing DNA-vaccine platform. Here is what you need to know from today's release. </p>
<p><strong>Business and corporate update</strong><br>For the first quarter, Inovio lost $10 million, or $0.05 a share, which was $0.01 higher than analysts had expected. However, Inovio's revenue came in at $2.4 million for the quarter, considerably higher than the consensus of $1.41 million. Nearly all revenue in the quarter was earned from Inovio's research agreement with <strong>Roche</strong>  (<span class="ticker">NASDAQOTH: <a data-id="220744" class="qsAdd qs-source-isssitthv0000001" href="http://caps.fool.com/Ticker/RHHBY.aspx">RHHBY</a></span>&nbsp;<a class="addToWatchListIcon qsAdd qs-source-iwlsitbut0000010" title="Add RHHBY to My Watchlist" href="http://my.fool.com/watchlist/add?ticker=RHHBY">&nbsp;</a>) , consisting of three developmental fees totaling $1.4 million.</p>
<p>The modest increase in loss per share was due primarily to an increase in research expenses, which came in at $8.5 million, compared to $5.1 million for the same period a year ago. Inovio ended the quarter with $116.8 million in cash and cash equivalents, with $63.3 million coming from an underwritten offering during the quarter. Based on its current burn rate and incoming revenue from its Roche deal, Inovio's cash runway should extend into 2017. </p>
<p><strong>Clinical update</strong><br>Most important, Inovio provided a brief update on clinical activities for its lead vaccine candidate, VGX-3100. According to the release, VGX-3100 is on track to by mid-2014 read out top-line data from its midstage trial as a potential treatment for late stage cervical pre-cancer to early stage pre-cancer. The trial is currently blinded, so management won't have much further insight until midyear. Even so, Inovio's management said it is preparing to push the vaccine into a late-stage trial, assuming the treatment meets its predefined efficacy and safety endpoints in its going study.</p>
<p>Additionally, Inovio said today it plans to test VGX-3100 in both HPV-caused cervical cancer and head and neck cancer in early stage studies later this year. These studies will incorporate an immune activator called IL-12 that couldincrease the immune response when used in conjunction with VGX-3100. </p>
<p>Turning to the company's clinical activities with Roche, Inovio plans on initiating an early stage study for its prostate cancer vaccine by the third quarter of this year. Animal studies have suggested this vaccine could trigger a powerful immune response in clinical testing, which is probably why Roche was interested in partnering in the first place. Moreover, Inovio will receive its first milestone payment upon the launch of the trial, giving investors more to look forward to for the company's strengthening balance sheet. </p>
<p><strong>Foolish wrap-up<br></strong>Inovio shares have dropped over 25% year to date. What's interesting is that this dramatic downturn hasn't been accompanied by any particular news. My take is that, in addition to the sector-wide biotech drop investors witnessed in March and April, short-term traders might be exiting the stock ahead of the top-line data readout for VGX-3100, assuming it will be negative. There is cause for concern because Inovio's vaccine platform has yet to be validated in a midstage trial. And if VGX-3100 fails in its current trial, the stock may return to its former sub-dollar territory.</p>
<p>That being said, you can't find many publicly traded developmental-stage vaccine makers these days, because these types of companies tend to be so valuable that large pharmas buy them up. Indeed, we know from <strong>Novavax</strong>'s  (<span class="ticker">NASDAQ: <a data-id="204769" class="qsAdd qs-source-isssitthv0000001" href="http://caps.fool.com/Ticker/NVAX.aspx">NVAX</a></span>&nbsp;<a class="addToWatchListIcon qsAdd qs-source-iwlsitbut0000010" title="Add NVAX to My Watchlist" href="http://my.fool.com/watchlist/add?ticker=NVAX">&nbsp;</a>)  first-quarter earnings call that it is attempting to stave off large pharma interest and remain independent in order to retain the tremendous value of its RSV franchise. If Inovio can surprise the market and report positive midstage data for VGX-3100 in a month or so, I suspect it will have the same problem. And that's not a bad problem to have.<br> </p>
<div class="sfr" id="pitch">
  <p><strong>Will this stock be your next multibagger?<br></strong>Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click <a href="http://www.fool.com/ecap/stock-advisor/sa-stocks2014-sfr/?aid=7301&amp;source=isaeditxt0000102">here</a> to download your free copy of "<a href="http://www.fool.com/ecap/stock-advisor/sa-stocks2014-sfr/?aid=7301&amp;source=isaeditxt0000102">The Motley Fool's Top Stock for 2014</a>" today.</p>
</div>                     <script type="text/javascript">                         var FoolAnalyticsData = FoolAnalyticsData || [];                           FoolAnalyticsData.push({                            eventType: "ArticlePitch",                            contentByline: "George Budwell",                            contentId: "cms.124571",                            contentTickers: "",                            contentTitle: "Here\'s What You Need to Know About Inovio Pharmaceuticals\' First-Quarter Earnings",                            hasVideo: "False",                            pitchId: "681",                            pitchTickers: "",                            pitchTitle: "",                            pitchType: "sfr",                            sfrId: ""                         });                     </script>                     <p></p>
                <div id="pitcherPitch"></div>
				

<script type="text/javascript" src="http://j.foolcdn.com/common/js/marketing/pitchengine.js?v=83336"></script>
 
<script>
    Fool.onContent(function() {
        if (typeof(window.infotronQueue) !== "undefined")
            window.infotronQueue.Register('pitch');

        var pitchEngine = PitchEngine();
        var pitchId = -1;
        var sessionCount = 1;
        var firstPageView = 0;

        if (typeof (FoolAnalyticsData) !== "undefined" && typeof (FoolAnalyticsData[0]) !== "undefined" && typeof (FoolAnalyticsData[0].pitchId) !== "undefined") {
            pitchId = FoolAnalyticsData[0].pitchId;
        }

        if (Fool.Cookie.exists('Visitor')) {
            var visitCountCookie = Fool.Cookie.getValues('Visitor')['visits'];
            if (typeof(visitCountCookie) !== "undefined") {
                sessionCount = pitchEngine.tryParseInt(visitCountCookie, 1); 
            }
        }

        pitchEngine.initialize({
            site: 'fool',
            placement: 'article_pitch',
            tickers: 'INO,NVAX,RHHBY',
            instrumentId: '215712,204769,220744',
            uid: '0',
            guid: '',
            isEcapped: false,
            isBuyer: false,
            containsPitchBase: false,
            productId: '',
            pitchId: pitchId,
            sessionCount: sessionCount,
            firstPageview: firstPageView,
            skin: '',
            pitchContainer: 'pitch'
        });
    });
</script>



                
                        
                                <!-- control -->
                            						
                						

				<!-- surphace end -->
				
				<!-- Third Party Content Additional Links (if any).  XML path and visibility is set according to Provider in code-behind -->
				


				
        		
        		
				
				
				
					
				<div class='footer'><p><em><a href="http://my.fool.com/profile/gbudwell/info.aspx">George Budwell</a> has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services <a href="http://www.fool.com/shop/newsletters/index.aspx?source=isiedilnk018048">free for 30 days</a>. We Fools may not all hold the same opinions, but we all believe that <a href="http://wiki.fool.com/Motley">considering a diverse range of insights</a> makes us better investors. The Motley Fool has a <a href="http://www.fool.com/Legal/fool-disclosure-policy.aspx">disclosure policy</a>.</em></p></div>
			
			</div><!-- /entry-content -->
					
		</div><!-- /content -->
		<br style="clear:both;" />
        
        
		<div id="articleTools">

			<p id="recModuleBottom">				
			  <span class="readComments"><a href="#commentsBoxAnchor">Read/Post Comments (4)</a></span>
				<span class="recModulePike"> | </span>
				<span class="recArticle">
	<span class="recInline">
		<a href="#" onclick="Recommendations.RecommendIt('0','2952688','Post', this);return false;">Recommend This Article (3)</a> 
	</span>
	<noscript>
		<span class="recInline">
			Recommended 3 Times
		</span>
  </noscript>


</span>
                
				<!-- AddThis Button BEGIN --> 
				<div class="shareLinks clearfix addthis_toolbox" id="horizontal_bottom_toolbox" >
					<a class="addthis_button_facebook_like" fb:like:layout="button_count"></a>
					<a class="addthis_button_tweet" tw:via="themotleyfool"></a>
					<!--<a class="addthis_button_google_plusone" g:plusone:size="medium"></a>-->
					<a class="addthis_button_email email_bg">Email</a>
					<a class="print_bg" href="/server/FoolPrint.asp?File=/investing/general/2014/05/12/heres-what-you-need-to-know-about-inovio-pharmaceu.aspx">Print</a>
					<a class="feedback_bg" href="http://www.fool.com/Help/Index.htm?display=EmailNews&amp;p=/investing/general/2014/05/12/heres-what-you-need-to-know-about-inovio-pharmaceu.aspx">Feedback</a>
                    <a class="addthis_counter addthis_pill_style"></a>
                    <script type="text/javascript"> var addthis_config = { "data_track_addressbar": true };</script>

				</div>	
				<script src="http://s7.addthis.com/js/250/addthis_widget.js#pubid=ra-4fccc73f4f57fb0a" type="text/javascript"></script>

			
			</p>
        
        	<!-- AddThis VERTICAL Buttons BEGIN -->
				<div class="addthis_toolbox addthis_floating_style addthis_counter_style"  id="vertical_toolbox">
					<a class="addthis_button_facebook_like" fb:like:layout="box_count"></a>
					<a class="addthis_button_tweet" tw:count="vertical" tw:via="themotleyfool"></a>
					<!--<a class="addthis_button_google_plusone" g:plusone:size="tall"></a>-->
                    <a class="addthis_button_linkedin_counter" li:counter="top"></a>
					<a class="addthis_button_email email_bg">Email</a>
					<a class="addthis_button_print print_bg">Print</a>
				</div>
               


		</div><!-- /articleTools -->

		
        
        
            <div class="promoboxAd">
                <div id="div-gpt-ad-470x300-0"></div><script type="text/javascript">var pitcherAds = pitcherAds || PitcherAds();pitcherAds.get({placement: "promobox",divId: "div-gpt-ad-470x300-0",site: "usmf.inv.investing",zone: "articles",width: 470,height: 300,pos: "",position: "0",seg: "default",tile: "3",sub: "default",port: "default",trades: "default",reg: "false",uid: "0",etfticker: "false",ret: "default",mgr: "default",funds: "default",goldticker: "false",bureau: "health-care",ord_aband: "default",series: "default",buckettarget: "default",swap: "false",sessionCount: "1",tenOrMoreSessions: "false",type: "269",adtags: "growth,health-care,pharma,tech",tickers: "INO,RHHBY,NVAX",src: ""});</script>
      	    </div>
        
        

		<div class="component" id="articleCommentsAjaxContainer">
			

<input type="hidden" name="ArticleID" id="ArticleID" value="2952688"/> 

<div id="comments">
	<a name="commentsBoxAnchor" id="commentsBoxAnchor"></a>
	<h3 class="boxTop">Comments from our Foolish Readers</h3>
	<p class="intro"><strong>Help us keep this a respectfully Foolish area!</strong> This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above.  Help us keep it clean and safe.  If you believe a comment is abusive or otherwise violates our <a href="http://www.fool.com/help/index.htm?display=newuser02">Fool's Rules</a>, please report it via the <img src="//g.foolcdn.com/art/article/icn_comment-redhand.gif" alt="Report this Comment" /> <strong>Report this Comment</strong> icon found on every comment.</p>

	<div id="ajaxPosts">
		
			<ul id="commentsList" class="truncated">
				
						<li id="comment966462">
							<div class="commentHead">
								<h6>
									<a href="#" title="Report this Comment" class="foolcop redflag"><span>Report this Comment</span></a>
									On May 12, 2014,
									at 2:20 PM, 
									<a href="http://boards.fool.com/Profile.asp?uid=1880596911"><strong>theNextThing</strong></a> wrote:
								</h6>
							</div>
							<div class="commentPost"><p><p rel="nofollow">Here's some snippet of “confident” sentiment spilled by Dr. Kim (about VGX-3100 P2 readout) in the Q&amp;A session during the 4Q 2013 Financial Result Conference Call :</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/ln15Qy" rel="nofollow">http://goo.gl/ln15Qy</a></p><p rel="nofollow">&lt;Q&gt; : ……… so the interleukin-12 and 28 as an augmentation for your vaccine is very interesting. Is that something you would pursue for the phase III cervical dysplasia program if phase II is positive?</p><p rel="nofollow"> </p><p rel="nofollow">&lt;A&gt; : Dr. J. Joseph Kim – President and Chief Executive Officer</p><p rel="nofollow"> </p><p rel="nofollow">…………… All in all, we have almost a dozen different immune activators in our portfolio, but … and … being able to utilize combinations, we have an immune activator that can generate higher levels of antibodies, … and so on.</p><p rel="nofollow">For the direct question of … in phase III, we certainly have the capability to do that if the need arises.</p><p rel="nofollow">But we feel very strongly that our levels of efficacy may not require the use of IL-12 immune activator………….. </p><p rel="nofollow">I believe INO can get it right soon(mid-2014) or later(in 3-8 years).</p><p rel="nofollow">I intent to follow / support / invested in INO virtually forever.</p><p rel="nofollow">(Unless, one of the big pharmas buys them out before INO hits its peak.)</p><p rel="nofollow">I know how long &amp; how much pain I can tolerate if needed.</p><p rel="nofollow">Everyone should do more DD on their own &amp; make their own assessments.</p></p></div>
								
						</li>
					
						<li id="comment966482">
							<div class="commentHead">
								<h6>
									<a href="#" title="Report this Comment" class="foolcop redflag"><span>Report this Comment</span></a>
									On May 12, 2014,
									at 3:01 PM, 
									<a href="http://boards.fool.com/Profile.asp?uid=1880596911"><strong>theNextThing</strong></a> wrote:
								</h6>
							</div>
							<div class="commentPost"><p><p rel="nofollow">Here’s some snippets of “confident” sentiment spilled by Dr. Kim (about VGX-3100 P2 readout) in the Q&amp;A session during the 4Q 2013 Financial Result Conference Call :</p><p rel="nofollow"> </p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/ln15Qy" rel="nofollow">http://goo.gl/ln15Qy</a></p><p rel="nofollow">&lt;Q&gt; : ……… so the interleukin-12 and 28 as an augmentation for your vaccine is very interesting. Is that something you would pursue for the phase III cervical dysplasia program if phase II is positive?</p><p rel="nofollow">&lt;A&gt; : Dr. J. Joseph Kim – President and Chief Executive Officer</p><p rel="nofollow"> </p><p rel="nofollow">…………… All in all, we have almost a dozen different immune activators in our portfolio, but … and … being able to utilize combinations, we have an immune activator that can generate higher levels of antibodies, … and so on.</p><p rel="nofollow"> </p><p rel="nofollow">For the direct question of … in phase III, we certainly have the capability to do that if the need arises.</p><p rel="nofollow"> </p><p rel="nofollow">But we feel very strongly that our levels of efficacy may not require the use of IL-12 immune activator………….. </p><p rel="nofollow">I believe INO can get it right soon(mid-2014) or later(in 3-8 years).</p><p rel="nofollow">I intent to follow / support / invested in INO virtually forever.</p><p rel="nofollow">(Unless, one of the big pharmas buys them out before INO hits its peak.)</p><p rel="nofollow">I know how long &amp; how much pain I can tolerate if needed.</p><p rel="nofollow">Everyone should do more DD on their own &amp; make their own assessments.</p></p></div>
								
						</li>
					
						<li id="comment966486">
							<div class="commentHead">
								<h6>
									<a href="#" title="Report this Comment" class="foolcop redflag"><span>Report this Comment</span></a>
									On May 12, 2014,
									at 3:07 PM, 
									<a href="http://boards.fool.com/Profile.asp?uid=1880596911"><strong>theNextThing</strong></a> wrote:
								</h6>
							</div>
							<div class="commentPost"><p><p rel="nofollow">INO is no ordinary biotech.</p><p rel="nofollow">Although, INO is having difficulty getting some respect in the PennyLand.</p><p rel="nofollow">I view INO as a future powerhouse for the following reasons :</p><p rel="nofollow">(Inovio’s Foundation Is Being Built With Four Pillars of Break-Through Technologies)</p><p rel="nofollow">1. SynCon DNA Vaccine “Platform&quot;.</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/pJA05w" rel="nofollow">http://goo.gl/pJA05w</a></p><p rel="nofollow">2. Electroporation DNA Vaccine delivery technology</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/9xnZX4" rel="nofollow">http://goo.gl/9xnZX4</a></p><p rel="nofollow">3. DNA-based Cytokine &amp; Chemokine Immune Boosters(Activators)</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/v281MW" rel="nofollow">http://goo.gl/v281MW</a></p><p rel="nofollow">4. DNA-based Monoclonal Antibody Therapy</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/m1x8D8" rel="nofollow">http://goo.gl/m1x8D8</a></p><p rel="nofollow">Note : Many of the Biotech companies have just one or two technologies.</p><p rel="nofollow"> </p><p rel="nofollow">1. SynCon DNA Vaccine “Platform&quot;.</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/pJA05w" rel="nofollow">http://goo.gl/pJA05w</a></p><p rel="nofollow">- Powerful, Highly Optimizable &amp; Broadly Applicable Platform : Recently showing consistency in generating “best-in-class” antigen/cancer specific T-cell &amp; antibody immune responses. Big pharmas are drooling all over it.</p><p rel="nofollow">(IN 2013, INO’s DNA vaccine platform was in-a-way validated with a big pharma partnership / licensing deal worth $400+ million by Roche. Roche acquired an exclusive worldwide license for Inovio’s DNA-based vaccines INO-5150 (targeting prostate cancer) and INO-1800 (targeting hepatitis B). And, for use of its electroporation technology for delivery of the products. <a rel="nofollow" href="http://goo.gl/KOXQhS" rel="nofollow">http://goo.gl/KOXQhS</a> <a rel="nofollow" href="http://goo.gl/4NgYzG" rel="nofollow">http://goo.gl/4NgYzG</a></p><p rel="nofollow">- Currently has DNA-based Cancer Vaccines in its pipeline that are designed to treat numerous cancers :</p><p rel="nofollow">Cervical Dysplasia (Pre-Cancer)</p><p rel="nofollow">Cervical Cancer</p><p rel="nofollow">Head &amp; Neck Cancer</p><p rel="nofollow">Prostate Cancer</p><p rel="nofollow">Breast Cancer</p><p rel="nofollow">Lung Cancer</p><p rel="nofollow">Melanoma</p><p rel="nofollow">Pancreatic Cancer</p><p rel="nofollow">(Pipeline : <a rel="nofollow" href="http://goo.gl/FMQRZY" rel="nofollow">http://goo.gl/FMQRZY</a> )</p><p rel="nofollow">i.e. 1</p><p rel="nofollow">- VGX-3100 SynCon vaccine for Cervical Dysplasia/Cancer : </p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/yhAbgF" rel="nofollow">http://goo.gl/yhAbgF</a> (Review the data-chart under the Study Data section)</p><p rel="nofollow">“Unprecedented T-cell responses not achieved by a DNA vaccine or any other non-replicating vaccine platform in humans.”</p><p rel="nofollow">Highest dose group achieved 83% T-cell responses in phase 1.</p><p rel="nofollow">(Highest dose used in phase 1 was administered to all of its phase 2 study patients due to its low/non-toxicity.)</p><p rel="nofollow">Dose used in phase 2 : 6mg (3mg of plasmid encoding for E6 &amp; E7 proteins for type 16 HPV + 3mg of plasmid encoding for E6 &amp; E7 proteins for type 18 HPV)</p><p rel="nofollow">VGX-3100 won “Best Therapeutic Vaccine(approved or in-development)” award at the World Vaccine Congress in 2013 &amp; 2014.</p><p rel="nofollow">Expecting top-line data read-out from phase 2 in mid-2014.</p><p rel="nofollow">(based on prior results, management is highly optimistic.)</p><p rel="nofollow">Review more data charts on pages 17-20 from this link : <a rel="nofollow" href="http://goo.gl/jJ33hG" rel="nofollow">http://goo.gl/jJ33hG</a></p><p rel="nofollow">i.e. 2</p><p rel="nofollow">- PENNVAX-B HIV Vaccine : </p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/jU6vOI" rel="nofollow">http://goo.gl/jU6vOI</a></p><p rel="nofollow">“Best-in-class” T-cell responses observed in 89% of Phase I subjects.</p><p rel="nofollow">Review data charts on pages 13-14 from this link : <a rel="nofollow" href="http://goo.gl/jJ33hG" rel="nofollow">http://goo.gl/jJ33hG</a></p><p rel="nofollow">i.e. 3</p><p rel="nofollow">- INO-1400 hTERT “Universal” Cancer Vaccine (MOST EXCITING)</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/XE6ENg" rel="nofollow">http://goo.gl/XE6ENg</a></p><p rel="nofollow">hTERT antigen is highly expressed in 85% of all human cancers.</p><p rel="nofollow">INO-1400 is design to specifically target hTERT antigens. (Thus, INO-1400 hTERT can be used to treat 85% of all cancer types.) Inovio has developed a highly optimized synthetic hTERT DNA vaccine with two mutations designed to target multiple cancers expressing the antigen hTERT, including :</p><p rel="nofollow">Non-small cell lung carcinoma</p><p rel="nofollow">Breast cancer</p><p rel="nofollow">Pancreatic cancer</p><p rel="nofollow">Melanoma</p><p rel="nofollow">Prostate cancer</p><p rel="nofollow">And, INO is working on 4-6 more of DNA cancer vaccines targeting “prevalent-type-antigens&quot; likes of hTERT, to be productized for testing by end of 2014.</p><p rel="nofollow">With the combination of these “prevalent-type-antigen&quot; cancer vaccines, Inovio expects to be able to address almost every cancer type out there.</p><p rel="nofollow"> </p><p rel="nofollow">This revolutionary approach is directly opposite from the early generation of genomic science/therapy.</p><p rel="nofollow"> </p><p rel="nofollow">Review data chart on page 23 of this link : <a rel="nofollow" href="http://goo.gl/jJ33hG" rel="nofollow">http://goo.gl/jJ33hG</a></p><p rel="nofollow">(I want to reiterate my opinion, if just 25% of all BioTech / Tech investors knew what INO-1400 hTERT is designed to do, INO would not be a $3 stock, haha :-) I wonder how the biotech investors invested in the following stocks would view Inovio(INO) : $AMGN, $ALNY, $BIIB, $CELG, $GILD, $MRK, $PBYI, $PCYC &amp; $REGN. (They may call it, “T-Cell King”?)</p><p rel="nofollow">2. Electroporation DNA Vaccine Delivery technology</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/9xnZX4" rel="nofollow">http://goo.gl/9xnZX4</a></p><p rel="nofollow">- 1000x enhancement in cellular uptake of DNA vaccine.</p><p rel="nofollow">(It is the secret source for overcoming two decade huddle of DNA delivery.)</p><p rel="nofollow">3. DNA-based Cytokine &amp; Chemokine Immune Boosters(Activators)</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/v281MW" rel="nofollow">http://goo.gl/v281MW</a></p><p rel="nofollow">- I believe the new portfolio of DNA-based Cytokine &amp; Chemokine Immune Boosters (Activators) can “thrust” INO over most of the huddles.</p><p rel="nofollow">- Adding to INO’s already “best-in-class” T-cell immune generating DNA vaccines, </p><p rel="nofollow">a new portfolio of DNA-based Cytokine &amp; Chemokine Immune Boosters is designed to enhance the T-cell &amp; antibody responses &amp; durabilities of its vaccines to treat more difficult types of cancers.</p><p rel="nofollow">- DNA-based Immune Booster(IL-12) will be used in the Phase 2 trial for INO-3112 Cervical Cancer. (in 1H)</p><p rel="nofollow">- DNA-based Immune Booster(IL-12) will be used in the Phase 2 trial for INO-3112 Head &amp; Neck Cancer. (in 1H)</p><p rel="nofollow"> </p><p rel="nofollow">- DNA-based Immune Booster(IL-33) will be used in the Phase 1/2a trial for INO-hTERT Breast Cancer. (in 2H)</p><p rel="nofollow">- DNA-based Immune Booster(IL-33) will be used in the Phase 1/2a trial for INO-hTERT Lung Cancer. (in 2H)</p><p rel="nofollow">- DNA-based Immune Booster(IL-33) will be used in the Phase 1/2a trial for INO-hTERT Pancreatic Cancer. (in 2H)</p><p rel="nofollow">- Inovio currently has the largest collection of Immune Boosters in the world. And, is working/scheduled to finish productizing the full spectrum of Immune Boosters for clinical testings by the end of 2014.</p><p rel="nofollow">- In my opinion, DNA-based Immune Boosters can nudge Inovio firmly into a leading cancer immunotherapy company.</p><p rel="nofollow">NOTE : </p><p rel="nofollow">According to Inovio CEO, Immune Boosters more-likely are not needed to treat “Pre-Cancerous” cases such as Cervical Dysplasia, based on the previous data, as the pre-cancer cells are not well established.</p><p rel="nofollow"> </p><p rel="nofollow">4. Monoclonal Antibody Therapy (mAb)</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/m1x8D8" rel="nofollow">http://goo.gl/m1x8D8</a></p><p rel="nofollow">- I believe INO’s latest portfolio of DNA-based Monoclonal Antibody(mAb) technology can really fine-tune the efficacy in defeating cancer &amp; infectious diseases.</p><p rel="nofollow">(Approximately $50+ billion market mAb alone.)</p><p rel="nofollow">I also have a lot of faith in INO’s dedicated world-renowned Scientific Advisory Board, Management &amp; Board of Directors.</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/h6wnYO" rel="nofollow">http://goo.gl/h6wnYO</a></p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/zR35kl" rel="nofollow">http://goo.gl/zR35kl</a></p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/ycTcnJ" rel="nofollow">http://goo.gl/ycTcnJ</a></p><p rel="nofollow">I especially believe in the dedications of Dr. Kim &amp; the Scientific Advisory Board.</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/KKCLF7" rel="nofollow">http://goo.gl/KKCLF7</a></p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/2sKLbX" rel="nofollow">http://goo.gl/2sKLbX</a></p><p rel="nofollow">I believe INO can get it right soon(mid-2014) or later(in 3-8 years).</p><p rel="nofollow">I intent to follow / support / invested in INO virtually forever.</p><p rel="nofollow">(Unless, one of the big pharmas buys them out before INO hits its peak.)</p><p rel="nofollow">I know how long &amp; how much pain I can tolerate if needed.</p><p rel="nofollow">Everyone should do more DD on their own (you most-likely can give more respect to INO) &amp; make their own assessments.</p><p rel="nofollow">P.S.</p><p rel="nofollow">Although, I hope INO allocates more efforts to defend itself from malicious bashers &amp; manipulators(NOT just on their fundamentals).</p></p></div>
								
						</li>
					
						<li id="comment966487">
							<div class="commentHead">
								<h6>
									<a href="#" title="Report this Comment" class="foolcop redflag"><span>Report this Comment</span></a>
									On May 12, 2014,
									at 3:08 PM, 
									<a href="http://boards.fool.com/Profile.asp?uid=1880596911"><strong>theNextThing</strong></a> wrote:
								</h6>
							</div>
							<div class="commentPost"><p><p rel="nofollow">INO is no ordinary biotech.</p><p rel="nofollow">Although, INO is having difficulty getting some respect in the PennyLand.</p><p rel="nofollow">I view INO as a future powerhouse for the following reasons :</p><p rel="nofollow">(Inovio’s Foundation Is Being Built With Four Pillars of Break-Through Technologies)</p><p rel="nofollow">1. SynCon DNA Vaccine “Platform&quot;.</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/pJA05w" rel="nofollow">http://goo.gl/pJA05w</a></p><p rel="nofollow">2. Electroporation DNA Vaccine delivery technology</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/9xnZX4" rel="nofollow">http://goo.gl/9xnZX4</a></p><p rel="nofollow">3. DNA-based Cytokine &amp; Chemokine Immune Boosters(Activators)</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/v281MW" rel="nofollow">http://goo.gl/v281MW</a></p><p rel="nofollow">4. DNA-based Monoclonal Antibody Therapy</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/m1x8D8" rel="nofollow">http://goo.gl/m1x8D8</a></p><p rel="nofollow">Note : Many of the Biotech companies have just one or two technologies.</p><p rel="nofollow"> </p><p rel="nofollow">1. SynCon DNA Vaccine “Platform&quot;.</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/pJA05w" rel="nofollow">http://goo.gl/pJA05w</a></p><p rel="nofollow">- Powerful, Highly Optimizable &amp; Broadly Applicable Platform : Recently showing consistency in generating “best-in-class” antigen/cancer specific T-cell &amp; antibody immune responses. Big pharmas are drooling all over it.</p><p rel="nofollow">(IN 2013, INO’s DNA vaccine platform was in-a-way validated with a big pharma partnership / licensing deal worth $400+ million by Roche. Roche acquired an exclusive worldwide license for Inovio’s DNA-based vaccines INO-5150 (targeting prostate cancer) and INO-1800 (targeting hepatitis B). And, for use of its electroporation technology for delivery of the products. <a rel="nofollow" href="http://goo.gl/KOXQhS" rel="nofollow">http://goo.gl/KOXQhS</a> <a rel="nofollow" href="http://goo.gl/4NgYzG" rel="nofollow">http://goo.gl/4NgYzG</a></p><p rel="nofollow">- Currently has DNA-based Cancer Vaccines in its pipeline that are designed to treat numerous cancers :</p><p rel="nofollow">Cervical Dysplasia (Pre-Cancer)</p><p rel="nofollow">Cervical Cancer</p><p rel="nofollow">Head &amp; Neck Cancer</p><p rel="nofollow">Prostate Cancer</p><p rel="nofollow">Breast Cancer</p><p rel="nofollow">Lung Cancer</p><p rel="nofollow">Melanoma</p><p rel="nofollow">Pancreatic Cancer</p><p rel="nofollow">(Pipeline : <a rel="nofollow" href="http://goo.gl/FMQRZY" rel="nofollow">http://goo.gl/FMQRZY</a> )</p><p rel="nofollow">i.e. 1</p><p rel="nofollow">- VGX-3100 SynCon vaccine for Cervical Dysplasia/Cancer : </p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/yhAbgF" rel="nofollow">http://goo.gl/yhAbgF</a> (Review the data-chart under the Study Data section)</p><p rel="nofollow">“Unprecedented T-cell responses not achieved by a DNA vaccine or any other non-replicating vaccine platform in humans.”</p><p rel="nofollow">Highest dose group achieved 83% T-cell responses in phase 1.</p><p rel="nofollow">(Highest dose used in phase 1 was administered to all of its phase 2 study patients due to its low/non-toxicity.)</p><p rel="nofollow">Dose used in phase 2 : 6mg (3mg of plasmid encoding for E6 &amp; E7 proteins for type 16 HPV + 3mg of plasmid encoding for E6 &amp; E7 proteins for type 18 HPV)</p><p rel="nofollow">VGX-3100 won “Best Therapeutic Vaccine(approved or in-development)” award at the World Vaccine Congress in 2013 &amp; 2014.</p><p rel="nofollow">Expecting top-line data read-out from phase 2 in mid-2014.</p><p rel="nofollow">(based on prior results, management is highly optimistic.)</p><p rel="nofollow">Review more data charts on pages 17-20 from this link : <a rel="nofollow" href="http://goo.gl/jJ33hG" rel="nofollow">http://goo.gl/jJ33hG</a></p><p rel="nofollow">i.e. 2</p><p rel="nofollow">- PENNVAX-B HIV Vaccine : </p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/jU6vOI" rel="nofollow">http://goo.gl/jU6vOI</a></p><p rel="nofollow">“Best-in-class” T-cell responses observed in 89% of Phase I subjects.</p><p rel="nofollow">Review data charts on pages 13-14 from this link : <a rel="nofollow" href="http://goo.gl/jJ33hG" rel="nofollow">http://goo.gl/jJ33hG</a></p><p rel="nofollow">i.e. 3</p><p rel="nofollow">- INO-1400 hTERT “Universal” Cancer Vaccine (MOST EXCITING)</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/XE6ENg" rel="nofollow">http://goo.gl/XE6ENg</a></p><p rel="nofollow">hTERT antigen is highly expressed in 85% of all human cancers.</p><p rel="nofollow">INO-1400 is design to specifically target hTERT antigens. (Thus, INO-1400 hTERT can be used to treat 85% of all cancer types.) Inovio has developed a highly optimized synthetic hTERT DNA vaccine with two mutations designed to target multiple cancers expressing the antigen hTERT, including :</p><p rel="nofollow">Non-small cell lung carcinoma</p><p rel="nofollow">Breast cancer</p><p rel="nofollow">Pancreatic cancer</p><p rel="nofollow">Melanoma</p><p rel="nofollow">Prostate cancer</p><p rel="nofollow">And, INO is working on 4-6 more of DNA cancer vaccines targeting “prevalent-type-antigens&quot; likes of hTERT, to be productized for testing by end of 2014.</p><p rel="nofollow">With the combination of these “prevalent-type-antigen&quot; cancer vaccines, Inovio expects to be able to address almost every cancer type out there.</p><p rel="nofollow"> </p><p rel="nofollow">This revolutionary approach is directly opposite from the early generation of genomic science/therapy.</p><p rel="nofollow"> </p><p rel="nofollow">Review data chart on page 23 of this link : <a rel="nofollow" href="http://goo.gl/jJ33hG" rel="nofollow">http://goo.gl/jJ33hG</a></p><p rel="nofollow">(I want to reiterate my opinion, if just 25% of all BioTech / Tech investors knew what INO-1400 hTERT is designed to do, INO would not be a $3 stock, haha :-) I wonder how the biotech investors invested in the following stocks would view Inovio(INO) : $AMGN, $ALNY, $BIIB, $CELG, $GILD, $MRK, $PBYI, $PCYC &amp; $REGN. (They may call it, “T-Cell King”?)</p><p rel="nofollow">2. Electroporation DNA Vaccine Delivery technology</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/9xnZX4" rel="nofollow">http://goo.gl/9xnZX4</a></p><p rel="nofollow">- 1000x enhancement in cellular uptake of DNA vaccine.</p><p rel="nofollow">(It is the secret source for overcoming two decade huddle of DNA delivery.)</p><p rel="nofollow">3. DNA-based Cytokine &amp; Chemokine Immune Boosters(Activators)</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/v281MW" rel="nofollow">http://goo.gl/v281MW</a></p><p rel="nofollow">- I believe the new portfolio of DNA-based Cytokine &amp; Chemokine Immune Boosters (Activators) can “thrust” INO over most of the huddles.</p><p rel="nofollow">- Adding to INO’s already “best-in-class” T-cell immune generating DNA vaccines, </p><p rel="nofollow">a new portfolio of DNA-based Cytokine &amp; Chemokine Immune Boosters is designed to enhance the T-cell &amp; antibody responses &amp; durabilities of its vaccines to treat more difficult types of cancers.</p><p rel="nofollow">- DNA-based Immune Booster(IL-12) will be used in the Phase 2 trial for INO-3112 Cervical Cancer. (in 1H)</p><p rel="nofollow">- DNA-based Immune Booster(IL-12) will be used in the Phase 2 trial for INO-3112 Head &amp; Neck Cancer. (in 1H)</p><p rel="nofollow"> </p><p rel="nofollow">- DNA-based Immune Booster(IL-33) will be used in the Phase 1/2a trial for INO-hTERT Breast Cancer. (in 2H)</p><p rel="nofollow">- DNA-based Immune Booster(IL-33) will be used in the Phase 1/2a trial for INO-hTERT Lung Cancer. (in 2H)</p><p rel="nofollow">- DNA-based Immune Booster(IL-33) will be used in the Phase 1/2a trial for INO-hTERT Pancreatic Cancer. (in 2H)</p><p rel="nofollow">- Inovio currently has the largest collection of Immune Boosters in the world. And, is working/scheduled to finish productizing the full spectrum of Immune Boosters for clinical testings by the end of 2014.</p><p rel="nofollow">- In my opinion, DNA-based Immune Boosters can nudge Inovio firmly into a leading cancer immunotherapy company.</p><p rel="nofollow">NOTE : </p><p rel="nofollow">According to Inovio CEO, Immune Boosters more-likely are not needed to treat “Pre-Cancerous” cases such as Cervical Dysplasia, based on the previous data, as the pre-cancer cells are not well established.</p><p rel="nofollow"> </p><p rel="nofollow">4. Monoclonal Antibody Therapy (mAb)</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/m1x8D8" rel="nofollow">http://goo.gl/m1x8D8</a></p><p rel="nofollow">- I believe INO’s latest portfolio of DNA-based Monoclonal Antibody(mAb) technology can really fine-tune the efficacy in defeating cancer &amp; infectious diseases.</p><p rel="nofollow">(Approximately $50+ billion market mAb alone.)</p><p rel="nofollow">I also have a lot of faith in INO’s dedicated world-renowned Scientific Advisory Board, Management &amp; Board of Directors.</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/h6wnYO" rel="nofollow">http://goo.gl/h6wnYO</a></p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/zR35kl" rel="nofollow">http://goo.gl/zR35kl</a></p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/ycTcnJ" rel="nofollow">http://goo.gl/ycTcnJ</a></p><p rel="nofollow">I especially believe in the dedications of Dr. Kim &amp; the Scientific Advisory Board.</p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/KKCLF7" rel="nofollow">http://goo.gl/KKCLF7</a></p><p rel="nofollow"><a rel="nofollow" href="http://goo.gl/2sKLbX" rel="nofollow">http://goo.gl/2sKLbX</a></p><p rel="nofollow">I believe INO can get it right soon(mid-2014) or later(in 3-8 years).</p><p rel="nofollow">I intent to follow / support / invested in INO virtually forever.</p><p rel="nofollow">(Unless, one of the big pharmas buys them out before INO hits its peak.)</p><p rel="nofollow">I know how long &amp; how much pain I can tolerate if needed.</p><p rel="nofollow">Everyone should do more DD on their own (you most-likely can give more respect to INO) &amp; make their own assessments.</p><p rel="nofollow">P.S.</p><p rel="nofollow">Although, I hope INO allocates more efforts to defend itself from malicious bashers &amp; manipulators(NOT just on their fundamentals).</p></p></div>
								
						</li>
					
			</ul>
				<a name="newCommentAnchor" id="newCommentAnchor"></a>
			<h5>Add your comment.</h5>
		
	
		
	</div>

	

	

	
	
		<div id="newComment" class="addNew commentTools" style="display:none">
			<p id="P1">
				Your Fool username<!-- of <strong>insert username here</strong>--> will be displayed with your comment.<br /><br />
				Please be respectful with your comments. Review our <a href="http://www.fool.com/help/index.htm?display=newuser02">Fool's Rules</a>.
			</p>
			<textarea name="txtBody" rows="12" cols="30" id="txtBody" class="textbox" onclick="Fool.Authenticate(null, function() { $('txtBody').readOnly=false; })" readonly="readonly"></textarea>
			<p class="small muted">Your comment may be delayed up to 15 minutes</p>
			<div class="buttons">
				<input type="button" id="btnSave" class="nl-button call-to-action" value="Post Your Comment" onclick="ArticleComments.doSave()" /> 
			</div>
		</div> 
	

	<script type="text/javascript">
		document.observe("dom:loaded", function () {
			ArticleComments.showTools();
		});
	</script>
	<noscript>
		<div id="jsWarning">
			<p>Javascript is required to comment on Fool articles.</p>
		</div>
	</noscript>
</div>






















		</div>
		<!--googleoff:all-->
		
<div class="compareBrokersAds">
	<h3 class="boxTop"><a href="/how-to-invest/broker/index.aspx?source=ifldbcdbx0000002">Compare Brokers</a></h3>
	<div class="compareBrokersBox">
		<script language="JavaScript" type="text/javascript" src="http://ad.doubleclick.net/adj/usmf.inv.investing/articles;pos=hlp_1;seg=default;src=;sz=88x31;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?"></script><noscript><a href="http://ad.doubleclick.net/jump/usmf.inv.investing/articles;pos=hlp_1;seg=default;src=;sz=88x31;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?" rel="nofollow" target="_blank"><img src="http://ad.doubleclick.net/ad/usmf.inv.investing/articles;pos=hlp_1;seg=default;src=;sz=88x31;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?" border="0" alt=""></a></noscript>
	</div>
	<div class="compareBrokersBox INGCompare">
		<script language="JavaScript" type="text/javascript" src="http://ad.doubleclick.net/adj/usmf.inv.investing/articles;pos=hlp_2;seg=default;src=;sz=88x31;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?"></script><noscript><a href="http://ad.doubleclick.net/jump/usmf.inv.investing/articles;pos=hlp_2;seg=default;src=;sz=88x31;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?" rel="nofollow" target="_blank"><img src="http://ad.doubleclick.net/ad/usmf.inv.investing/articles;pos=hlp_2;seg=default;src=;sz=88x31;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?" border="0" alt=""></a></noscript>
	</div>
	<div class="compareBrokersBox">
		<script language="JavaScript" type="text/javascript" src="http://ad.doubleclick.net/adj/usmf.inv.investing/articles;pos=hlp_3;seg=default;src=;sz=88x31;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?"></script><noscript><a href="http://ad.doubleclick.net/jump/usmf.inv.investing/articles;pos=hlp_3;seg=default;src=;sz=88x31;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?" rel="nofollow" target="_blank"><img src="http://ad.doubleclick.net/ad/usmf.inv.investing/articles;pos=hlp_3;seg=default;src=;sz=88x31;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?" border="0" alt=""></a></noscript>
	</div>
	<div class="compareBrokersBox">
		<script language="JavaScript" type="text/javascript" src="http://ad.doubleclick.net/adj/usmf.inv.investing/articles;pos=hlp_4;seg=default;src=;sz=88x31;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?"></script><noscript><a href="http://ad.doubleclick.net/jump/usmf.inv.investing/articles;pos=hlp_4;seg=default;src=;sz=88x31;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?" rel="nofollow" target="_blank"><img src="http://ad.doubleclick.net/ad/usmf.inv.investing/articles;pos=hlp_4;seg=default;src=;sz=88x31;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?" border="0" alt=""></a></noscript>
	</div>
	<a href="/how-to-invest/broker/disclosure.aspx?source=compare" class="disclosure">Fool Disclosure</a>
</div>
		

<div class="sponsoredLinksAd">
    <script language="JavaScript" type="text/javascript" src="http://ad.doubleclick.net/adj/usmf.inv.investing/articles;pos=splinks;seg=default;src=;sz=1x1;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?"></script><noscript><a href="http://ad.doubleclick.net/jump/usmf.inv.investing/articles;pos=splinks;seg=default;src=;sz=1x1;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?" rel="nofollow" target="_blank"><img src="http://ad.doubleclick.net/ad/usmf.inv.investing/articles;pos=splinks;seg=default;src=;sz=1x1;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?" border="0" alt=""></a></noscript>
</div>

<div class="sponsoredLinksAd" style="display:none">
        <span style="font-size:10pt"><a href="http://www.fool.com/ecap/stock-advisor/sa-web-goes-dark/?aid=7126&amp;source=esazactxt0860023" target="_blank"><b> R.I.P. Internet -- 1969-2014</b></a><br>
        At only 45 years old... the Internet will be laid to rest in 2014. And Silicon Valley is thrilled. Because they know... The Economist believes the death of the Internet "will be transformative." In fact, the CEO of Cisco Systems -- one of the largest tech companies on the planet -- says somebody's going to bank "14.4 trillion in profit from one concept alone." 
        <a href="http://www.fool.com/ecap/stock-advisor/sa-web-goes-dark/?aid=7126&amp;source=esazactxt0860023" target="_blank">Click here for a FREE video that gives you what you need to capitalize on the little-known company behind this concept.</a></span></td>
</div>		

		<p class="debug">DocumentId: 2952688, ~/Articles/ArticleHandler.aspx, 6/6/2014 1:43:08 AM</p>
		<!-- do not remove this comment - articlescontent -->
		
	</div><!-- /primary -->

	

<fieldset id="foolcop">

	<h3>Report This Comment</h3>

	<p>
		Use this area to report a comment that you believe 
		is in violation of the community guidelines. Our 
		team will review the entry and take any appropriate 
		action.
	</p>

	<input type="hidden" name="whichComment" id="whichComment" value="" />
	<input type="hidden" name="commentContent" id="commentContent" value="" />

	<textarea name="reporterNote" id="reporterNote" rows="4" cols="18"></textarea>

	<div class="buttons">
		<input class="button" name="reportToFoolCop" id="reportToFoolCop" type="submit" value="Send this Report" />
		<input class="button" name="cancelFoolCop" id="cancelFoolCop" type="submit" value="Cancel" />
	</div>
</fieldset>

<div id="progress-indicator">

	<img alt="" src="http://g.foolcdn.com/art/newsletters/22/site/icn_progress.gif" />

	<h3>Sending report...</h3>

</div>

	
	
	<!-- AdA.Master -->
	<!--googleoff:all-->
	<div id="secondary" class="column">
	    
        
        
            <div class="myWatchlistModule clearfix round padded marginB">
                <div class="floatL marginR">
                    <a href="http://my.fool.com/profile/gbudwell/featured.aspx"><img src="?v=66201401"/></a>
                    <div class="hMarginT">
                        <strong class="subtle"><a class="button small" href="http://my.fool.com/profile/gbudwell/featured.aspx">Profile</a></strong>
                    </div>
                </div>
                <div>
                    <p class="minMarginB">
                        <strong>George Budwell</strong><br/>
                        <span class="small muted">gbudwell</span>
                    </p>
                    <p>George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies. </p>
                </div>
            </div>
 

        <div class="ad-336x280">
			<div id="div-gpt-ad-336x280-0"></div><script type="text/javascript">var pitcherAds = pitcherAds || PitcherAds();pitcherAds.get({placement: "bigbox_article",divId: "div-gpt-ad-336x280-0",site: "usmf.inv.investing",zone: "articles",width: 336,height: 280,pos: "",position: "0",seg: "default",tile: "8",sub: "default",port: "default",trades: "default",reg: "false",uid: "0",etfticker: "false",ret: "default",mgr: "default",funds: "default",goldticker: "false",bureau: "health-care",ord_aband: "default",series: "default",buckettarget: "default",swap: "false",sessionCount: "1",tenOrMoreSessions: "false",type: "269",adtags: "growth,health-care,pharma,tech",tickers: "INO,RHHBY,NVAX",src: ""});</script>
		</div>
        
 	    <div class="round clearfix">
			<div id="todaysMarket" class="component round">
				<h3>Today's Market</h3>
		        
<table cellspacing="0" cellpadding="0">
	
	<tfoot>
		<tr>
			<td colspan="5" class="updated txtR">
				<div class="fl txtR">
					<span class="ago">updated 4 hours ago</span>
					<span class="sponsoredBy">Sponsored by:</span>
				</div>
				<div class="fl sponsor">
					<script language="JavaScript" type="text/javascript" src="http://ad.doubleclick.net/adj/usmf.inv.investing/articles;pos=;seg=default;src=;sz=88x33;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=6;ord=62663609?"></script><noscript><a href="http://ad.doubleclick.net/jump/usmf.inv.investing/articles;pos=;seg=default;src=;sz=88x33;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=6;ord=62663609?" rel="nofollow" target="_blank"><img src="http://ad.doubleclick.net/ad/usmf.inv.investing/articles;pos=;seg=default;src=;sz=88x33;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=6;ord=62663609?" border="0" alt=""></a></noscript>
				</div>
			</td>
		</tr>
	</tfoot>

	<tbody>

		<tr class="clickable dji active">
			<td class="image up">
				<img src="http://g.foolcdn.com/common/img/ico/arrows/arrow_up_small.png">
			</td>
			<td class="index unvisit">
				<a class="unvisit qsAdd qs-source-ihpdspmki0000001" href="http://caps.fool.com/ticker/^DJI.aspx">DOW</a>
			</td>
			<td class="value">
				16,836.11
			</td>
			<td class="change up">
				98.58 
			</td>
			<td class="percentChange up">
				0.59%
			</td>
		</tr>

		<tr class="clickable gspc">
			<td class="image up">
				<img src="http://g.foolcdn.com/common/img/ico/arrows/arrow_up_small.png">
			</td>
			<td class="index unvisit">
				<a class="unvisit qsAdd qs-source-ihpdspmki0000001" href="http://caps.fool.com/ticker/^GSPC.aspx">S&amp;P 500</a>
			</td>
			<td class="value">
				1,940.46
			</td>
			<td class="change up">
				12.58 
			</td>
			<td class="percentChange up">
				0.65%
			</td>
		</tr>

		<tr class="clickable ixic">
			<td class="image up">
				<img src="http://g.foolcdn.com/common/img/ico/arrows/arrow_up_small.png">
			</td>
			<td class="index unvisit">
				<a class="unvisit qsAdd qs-source-ihpdspmki0000001" href="http://caps.fool.com/ticker/^IXIC.aspx">NASD</a>
			</td>
			<td class="value">
				4,296.23
			</td>
			<td class="change up">
				44.59 
			</td>
			<td class="percentChange up">
				1.05%
			</td>
		</tr>

	</tbody>
</table>

			</div>
		</div>

		
		
		
		
		<div class="round clearfix">
			<!-- TODO: Remove Stock of the Day and use a custom controller when user is not registered-->			
			
			

<div id="myWatchlist" class="component round whiteShield hPadded">

	<div class="hPadded">
		<h3 class="flushB">Create My Watchlist</h3>
		<p class="small flushB"><a class="qsAdd qs-source-iwlsitlnk0000014" href="http://my.fool.com/watchlist">Go to My Watchlist</a></p>
	</div>
	<div class="muted hPadded hMarginB meta ruledT ruledB">
		<h5 class="hMarginB">You don't seem to be following any stocks yet!</h5>
		<p class="hMarginB">Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.</p>
	</div>
	
	 
	<div id="addToMyWatchlist" class="capsBlueBox ruled hPadded clearfix hidden">
		<input type="text" placeholder="Enter ticker symbols..." name="scorecard-add-tickers" id="scorecard-add-tickers" class="floatL" tabindex="1"/>
		<strong class="subtle"><input type="button" value="+ Add" id="scorecard-add-button" class="submitButton button stroked round floatR" tabindex="2" /></strong>
	</div>
	<p class="xsmall txtC muted flushB">Data delayed up to 5 minutes</p>
</div>
			
					<div id="recommendedHeadlines" class="recommendedHeadlines headlinesBox component">
  <h3>Most Popular Articles</h3><a name="recommendedHeadlines"></a><ol>
    <li><a class="qsAdd qs-source-ihpdspmra0000002 qs-lidx-1" href="/investing/general/2014/05/31/what-is-the-internet-of-things-we-trekked-to-the-a.aspx?source=ihpsitth0000001">What Is "The Internet of Things"?</a></li>
    <li><a class="qsAdd qs-source-ihpdspmra0000002 qs-lidx-2" href="/investing/general/2014/05/24/the-big-picture-buy-thesis-for-whole-foods.aspx?source=iaasitlnk0000003">The Case for Whole Foods</a></li>
    <li><a class="qsAdd qs-source-ihpdspmra0000002 qs-lidx-3" href="/investing/general/2014/05/31/6-insights-for-investors-from-the-best-essay-eve-2.aspx?source=iaasitlnk0000003">Insights From Best Essay Ever</a></li>
    <li><a class="qsAdd qs-source-ihpdspmra0000002 qs-lidx-4" href="/investing/general/2014/05/16/an-interview-with-hedge-fund-manager-whitney-tilso.aspx">An Interview With Whitney Tilson</a></li>
    <li><a class="qsAdd qs-source-ihpdspmra0000002 qs-lidx-5" href="/investing/general/2014/05/30/interview-with-josh-brown-how-the-punditry-busines.aspx">Interview with Josh Brown</a></li>
  </ol>
</div>
				                                                                                      
		</div>
		
		<div class="ad-336x280">
			<div id="div-gpt-ad-336x281-0"></div><script type="text/javascript">var pitcherAds = pitcherAds || PitcherAds();pitcherAds.get({placement: "bigbox_article",divId: "div-gpt-ad-336x281-0",site: "usmf.inv.investing",zone: "articles",width: 336,height: 281,pos: "",position: "1",seg: "default",tile: "9",sub: "default",port: "default",trades: "default",reg: "false",uid: "0",etfticker: "false",ret: "default",mgr: "default",funds: "default",goldticker: "false",bureau: "health-care",ord_aband: "default",series: "default",buckettarget: "default",swap: "false",sessionCount: "1",tenOrMoreSessions: "false",type: "269",adtags: "growth,health-care,pharma,tech",tickers: "INO,RHHBY,NVAX",src: ""});</script>
		</div>
		
		<div class="round clearfix">
			

<div id="relatedTickers" class="component round">
	<h3>
		Related Tickers
	</h3>
	<div class="timestamp">
		6/5/2014 4:00 PM
	</div>

    
    <table class="tableNaked relatedTicker" cellpadding="0" cellspacing="0" itemscope="itemscope" itemtype="http://schema.org/Intangible/FinancialQuote">
		<tbody>
			<tr class="priceInfo">
				<td class="ticker">
				    <meta itemprop="id" content="215712" />
				    <meta itemprop="exchange" content="NYSEMKT" />
				    <meta itemprop="tickerSymbol" content="INO" />
                    <meta itemprop="url" content="http://caps.fool.com/ticker/INO.aspx" />
					<a href="http://caps.fool.com/ticker/INO.aspx" class="qsAdd qs-source-irlsitlnk0000001 qs-lidx-1">INO</a>
				</td>
				<td class="currentPrice">
				    <meta itemprop="price" content="2.31" />
					$2.31
				</td>
				<td class="movementDirection">
					<img src="http://g.foolcdn.com/common/img/ico/arrows/arrow_Up_medium.png" height="13" width="17" alt="Up" />
				</td>
				<td class="priceChange pos">
				    <meta itemprop="priceChange" content="+0.03" />
					+0.03
				</td>
				<td class="pricePercentChange pos">
				    <meta itemprop="priceChangePercent" content="+1.32" />
					+1.32%
				</td>
			</tr>
			<tr>
				<td class="companyName" colspan="2">
					Inovio Biomedical&#8230;
				</td>
				<td class="capsRating" colspan="3">
				<span class="capsRating">
					CAPS Rating: 
					<img
						alt="**" 
						src="http://g.foolcdn.com/art/ratings/foolcaps_lrg_two.gif" 
						class="infoTip" 
						title="2 Stars: Unattractive" />
				</span>
				</td>
			</tr>
		</tbody>
	</table>


    
    <table class="tableNaked relatedTicker" cellpadding="0" cellspacing="0" itemscope="itemscope" itemtype="http://schema.org/Intangible/FinancialQuote">
		<tbody>
			<tr class="priceInfo">
				<td class="ticker">
				    <meta itemprop="id" content="204769" />
				    <meta itemprop="exchange" content="NASDAQ" />
				    <meta itemprop="tickerSymbol" content="NVAX" />
                    <meta itemprop="url" content="http://caps.fool.com/ticker/NVAX.aspx" />
					<a href="http://caps.fool.com/ticker/NVAX.aspx" class="qsAdd qs-source-irlsitlnk0000001 qs-lidx-2">NVAX</a>
				</td>
				<td class="currentPrice">
				    <meta itemprop="price" content="4.52" />
					$4.52
				</td>
				<td class="movementDirection">
					<img src="http://g.foolcdn.com/common/img/ico/arrows/arrow_Down_medium.png" height="13" width="17" alt="Down" />
				</td>
				<td class="priceChange neg">
				    <meta itemprop="priceChange" content="-0.56" />
					-0.56
				</td>
				<td class="pricePercentChange neg">
				    <meta itemprop="priceChangePercent" content="-11.02" />
					-11.02%
				</td>
			</tr>
			<tr>
				<td class="companyName" colspan="2">
					Novavax, Inc.
				</td>
				<td class="capsRating" colspan="3">
				<span class="capsRating">
					CAPS Rating: 
					<img
						alt="**" 
						src="http://g.foolcdn.com/art/ratings/foolcaps_lrg_two.gif" 
						class="infoTip" 
						title="2 Stars: Unattractive" />
				</span>
				</td>
			</tr>
		</tbody>
	</table>


    
    <table class="tableNaked relatedTicker" cellpadding="0" cellspacing="0" itemscope="itemscope" itemtype="http://schema.org/Intangible/FinancialQuote">
		<tbody>
			<tr class="priceInfo">
				<td class="ticker">
				    <meta itemprop="id" content="220744" />
				    <meta itemprop="exchange" content="NASDAQOTH" />
				    <meta itemprop="tickerSymbol" content="RHHBY" />
                    <meta itemprop="url" content="http://caps.fool.com/ticker/RHHBY.aspx" />
					<a href="http://caps.fool.com/ticker/RHHBY.aspx" class="qsAdd qs-source-irlsitlnk0000001 qs-lidx-3">RHHBY</a>
				</td>
				<td class="currentPrice">
				    <meta itemprop="price" content="37.74" />
					$37.74
				</td>
				<td class="movementDirection">
					<img src="http://g.foolcdn.com/common/img/ico/arrows/arrow_Up_medium.png" height="13" width="17" alt="Up" />
				</td>
				<td class="priceChange pos">
				    <meta itemprop="priceChange" content="+0.26" />
					+0.26
				</td>
				<td class="pricePercentChange pos">
				    <meta itemprop="priceChangePercent" content="+0.69" />
					+0.69%
				</td>
			</tr>
			<tr>
				<td class="companyName" colspan="2">
					Roche Holding Ltd.&#8230;
				</td>
				<td class="capsRating" colspan="3">
				<span class="capsRating">
					CAPS Rating: 
					<img
						alt="*****" 
						src="http://g.foolcdn.com/art/ratings/foolcaps_lrg_five.gif" 
						class="infoTip" 
						title="5 Stars: The Best" />
				</span>
				</td>
			</tr>
		</tbody>
	</table>



</div>


		</div>
		
		<div class="sideBySideAds clearfix">
			<div class="left">
				<script language="JavaScript" type="text/javascript" src="http://ad.doubleclick.net/adj/usmf.inv.investing/articles;pos=right_1;seg=default;src=;sz=125x125;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=11;ord=62663609?"></script><noscript><a href="http://ad.doubleclick.net/jump/usmf.inv.investing/articles;pos=right_1;seg=default;src=;sz=125x125;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=11;ord=62663609?" rel="nofollow" target="_blank"><img src="http://ad.doubleclick.net/ad/usmf.inv.investing/articles;pos=right_1;seg=default;src=;sz=125x125;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=11;ord=62663609?" border="0" alt=""></a></noscript>
			</div>
			<div class="right">
				<script language="JavaScript" type="text/javascript" src="http://ad.doubleclick.net/adj/usmf.inv.investing/articles;pos=right_2;seg=default;src=;sz=125x125;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=12;ord=62663609?"></script><noscript><a href="http://ad.doubleclick.net/jump/usmf.inv.investing/articles;pos=right_2;seg=default;src=;sz=125x125;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=12;ord=62663609?" rel="nofollow" target="_blank"><img src="http://ad.doubleclick.net/ad/usmf.inv.investing/articles;pos=right_2;seg=default;src=;sz=125x125;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=12;ord=62663609?" border="0" alt=""></a></noscript>
			</div>
		</div>
	
		<div class="round clearfix">
			
			<div id="FacebookLikeBox">
				<iframe 
					src="http://www.facebook.com/plugins/likebox.php?href=http%3A%2F%2Fwww.facebook.com%2FTheMotleyFool&amp;width=292&amp;colorscheme=light&amp;show_faces=true&amp;stream=false&amp;header=true&amp;height=288" 
					scrolling="no" 
					frameborder="0" 
					style="border:none; overflow:hidden; width:292px; height:288px;" 
					allowTransparency="true">
				</iframe>
			</div>

		</div>



	</div><!-- /secondary -->
	<!--googleon:all-->
	<!-- /AdA.Master -->

	<!-- /ArticlesContent.Master -->
    <div id="informTickerReportAd"></div>

        </div>

		</div>
	</div>

		
		<!--googleoff: all--><br clear="all"><div id="footer">
  <div class="grid">
    <div class="column span-25">
      <ul>
        <li class="first"><a href="http://www.fool.com/" class="qsAdd qs-source-ihpftrlnk0000001" title="Home">Home</a></li>
        <li><a href="http://www.fool.com/Press/History.htm?ref=BTMP" class="qsAdd qs-source-ihpftrlnk0000001" title="About The Motley Fool">About The Motley Fool</a></li>
        <li><a href="http://www.fool.com/help/index.htm?display=about02&amp;ref=BTMP" class="qsAdd qs-source-ihpftrlnk0000001" title="Fool Disclosure">Fool Disclosure</a></li>
        <li><a href="http://wiki.fool.com/Motley_Fool_Money_Radio_Show" class="qsAdd qs-source-ihpftrlnk0000001" title="Radio Show">Radio Show</a></li>
        <li><a href="http://www.fool.com/Jobs/?ref=BTMP" class="qsAdd qs-source-ihpftrlnk0000001" title="Work at The Fool">Work at The Fool</a></li>
        <li><a href="http://www.fool.com/help/index.htm?display=about01&amp;ref=BTMP" class="qsAdd qs-source-ihpftrlnk0000001" title="Member Services">Member Services</a></li>
      </ul>
      <ul>
        <li class="first"><a href="http://www.fool.com/legal/contact-us.aspx" class="qsAdd qs-source-ihpftrlnk0000001" title="Advertise with The Fool">Advertise with The Fool</a></li>
        <li><a href="http://www.fool.com/help/index.htm?display=newuser03" class="qsAdd qs-source-ihpftrlnk0000001" title="Privacy Policy">Privacy Policy</a></li>
        <li><a href="http://www.fool.com/Account/Freemailsubscribe.aspx?ref=BTMP" class="qsAdd qs-source-ihpftrlnk0000001" title="Email Subscriptions">Email Subscriptions</a></li>
        <li><a href="http://www.fool.com/about/headlines/rss.htm?ref=BTMP" class="qsAdd qs-source-ihpftrlnk0000001" title="RSS Headlines"><img alt="RSS" class="rssLogo" src="http://g.foolcdn.com/img/rss.gif"> RSS Headlines</a></li>
        <li><a href="http://www.fool.com/help/index.htm?display=default&amp;ref=BTMP" class="qsAdd qs-source-ihpftrlnk0000001" title="Help">Help</a></li>
        <li><a href="http://www.fool.com/help/index.htm?display=morehelp01&amp;ref=BTMP" class="qsAdd qs-source-ihpftrlnk0000001" title="Site Map">Site Map</a></li>
        <li><a href="http://www.fool.co.uk/" class="qsAdd qs-source-ihpftrlnk0000001" title="Fool UK"><img alt="Fool UK" class="foolUkLogo" src="http://g.foolcdn.com/img/uk.gif"> Fool UK</a></li>
      </ul>
      <ul id="foolFriends">
        <li class="first">Fool Friends: </li>
        <li class="first"><a rel="nofollow" href="http://finance.yahoo.com/" target="_blank" title="Yahoo Finance">Yahoo Finance</a></li>
        <li><a rel="nofollow" href="http://www.money.msn.com/" target="_blank" title="MSN Money">MSN Money</a></li>
        <li><a rel="nofollow" href="http://www.dailyfinance.com/" target="_blank" title="AOL Business News">AOL Business News</a></li>
        <li><a href="http://www.mint.com/" target="_blank" title="Mint">Mint Personal Finance Software</a></li>
        <li><a href="http://www.lovemoney.com/" target="_blank" title="lovemoney.com">lovemoney.com</a></li>
      </ul>
      <ul id="legal">
        <li class="first"><a href="http://www.fool.com/help/index.htm?display=about03&amp;ref=BTMP" class="qsAdd qs-source-ihpftrlnk0000001" title="Copyright, Trademark and Patent Information">Copyright, Trademark and Patent Information</a></li>
        <li><a href="http://www.fool.com/help/index.htm?display=newuser02" title="Terms of Use">Terms of Use</a>
							© 1995 -
							2014
							The Motley Fool. All rights reserved.
                    	</li>
      </ul>
    </div><br><p class="attrib xMarginT flushB">
					BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.<br>
					Real-Time prices provided by <a href="http://www.batstrading.com/" target="_blank">BATS</a>. Market data provided by <a href="http://www.interactivedata.com/" target="_blank">Interactive Data</a>.<br>
					Company fundamental data provided by <a href="http://fundamentals.morningstar.com/" target="_blank">Morningstar</a>. Earnings Estimates and Analyst Ratings provided by <a href="http://www.zacks.com/" target="_blank">Zacks</a>.<br>
					SEC Filings and Insider Transactions provided by Edgar Online.<br>
					Powered and implemented by <a href="http://www.interactivedata.com/idms/" target="_blank">Interactive Data Managed Solutions</a>. <a href="javascript:void(0);" onclick="javascript:var win = window.open('http://caps.fool.com/idcterms.htm', '','width=400,height=300,status=0,resizable=yes,scrollbars=yes');return false;" title="Interactive Data Terms &amp; Conditions. Opens in a new browser window.">Terms &amp; Conditions</a><br><a href="http://www.interactivedata.com/" target="_blank"><img alt="Interactive Data" class="idcLogo" src="http://g.foolcdn.com/img/topNav/idc.gif"></a></p>
  </div>
  <div id="fn-serverinfo">156ms USEQ\WEB29
<!-- do not remove this comment --><!-- size mapping  failed --></div><script language="JavaScript" type="text/javascript" src="http://ad.doubleclick.net/adj/usmf.inv.investing/articles;pos=;seg=default;src=;sz=3x3;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=13;ord=62663609?"></script><noscript><a href="http://ad.doubleclick.net/jump/usmf.inv.investing/articles;pos=;seg=default;src=;sz=3x3;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=13;ord=62663609?" rel="nofollow" target="_blank"><img src="http://ad.doubleclick.net/ad/usmf.inv.investing/articles;pos=;seg=default;src=;sz=3x3;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=13;ord=62663609?" border="0" alt=""></a></noscript><script language="JavaScript" type="text/javascript" src="http://ad.doubleclick.net/adj/usmf.inv.investing/articles;pos=;seg=default;src=;sz=1x5;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?"></script><noscript><a href="http://ad.doubleclick.net/jump/usmf.inv.investing/articles;pos=;seg=default;src=;sz=1x5;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?" rel="nofollow" target="_blank"><img src="http://ad.doubleclick.net/ad/usmf.inv.investing/articles;pos=;seg=default;src=;sz=1x5;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?" border="0" alt=""></a></noscript></div><script type="text/javascript">
			var _gaq = _gaq || [];
			_gaq.push(['_setAccount', 'UA-3262475-1']);
			_gaq.push(['_trackPageview']);

			(function() {
			var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
			ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
			var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);
			})();
		</script><script type="text/javascript">_qacct = "p-77sCb6T55qLV6";</script><script type="text/javascript" src="http://secure.quantserve.com/quant.js"></script><noscript><a href="http://www.quantcast.com/p-77sCb6T55qLV6" target="_blank"><img style="display: none;" border="0" height="1" width="1" alt="Quantcast" src="http://secure.quantserve.com/pixel/p-77sCb6T55qLV6.gif"></a></noscript><script type="text/javascript">var tcdacmd="dt";</script><script src="http://an.tacoda.net/an/18382/slf.js" type="text/javascript"></script><script type="text/javascript">
			// 
			(function () {
				var d = new Image(1, 1);
				d.onerror = d.onload = function () {
					d.onerror = d.onload = null;
				};
				d.src = ["//secure-us.imrworldwide.com/cgi-bin/m?ci=us-503335h&cg=0&cc=1&si=", escape(window.location.href), "&rp=", escape(document.referrer), "&ts=compact&rnd=", (new Date()).getTime()].join('');
			})();
			// 
		</script><noscript>
  <div><img src="//secure-us.imrworldwide.com/cgi-bin/m?ci=us-503335h&amp;cg=0&amp;cc=1&amp;ts=noscript" width="1" height="1" alt=""></div>
</noscript><!--googleon: all-->
		
	
	
	<script src="/common/js/fool/analytics.js"></script>
       
    <div id="fb-root"></div>
    <script type="text/javascript">
        window.fbAsyncInit = function() {
            FB.init({
                appId: '50808187550',
                status: true, // check login status
                cookie: true, // enable cookies to allow the server to access the session
                xfbml: true,  // parse XFBML
                oauth: true
            });
            FB.Event.subscribe('edge.create', function(targetUrl) { // ga subscribe to likes
                _gaq.push(['_trackSocial', 'facebook', 'like', targetUrl]);
            });
            FB.Event.subscribe('edge.remove', function(targetUrl) { // ga subscribe to unlikes
                _gaq.push(['_trackSocial', 'facebook', 'unlike', targetUrl]);
            });
        };
        (function() {
            var e = document.createElement('script');
            e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js';
            e.async = true;
            document.getElementById('fb-root').appendChild(e);
        } ()); 
    </script>
			       

	
		    
			 <div id="ticklePrefixTemplate" style="display:none" class="txtC ruledT ruledB hPaddedB hPaddedT hMarginB hMarginT topTickle small"><strong><span class="muted"><span class="uppercase">Article Preview</span> &mdash; For full access, </span><a href="#lastVisibleParagraph">register below, it's free</a></strong></div>
             <div style="display:none" class="txtC big xMarginT xMarginB" id="bottomTickle"><span class="title"><strong>To keep reading, <a href="/Landing/TMF/Registration.aspx?dest=#{articleUrl}" class="popReg">click here, it's free</a> or <a class="popLogin" href="/secure/login.aspx?returnUrl=#{articleUrl}">login here</a></strong></span><div id="bottomTickleFrame"><iframe src="/common/ecap/tickle.aspx?source=#{sourceCode}&returnUrl=#{articleUrl}" width="100%" height="100%" id="tickle"></iframe></div></div>
		
			<script type="text/javascript">
			    Fool.onContent(function () { if (Article.Tickle) { Tickle = new Article.Tickle(); } });
			</script>
		<script language="JavaScript" type="text/javascript" src="http://ad.doubleclick.net/adj/usmf.inv.investing/articles;pos=overlay;seg=default;src=;sz=1x3;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?"></script><noscript><a href="http://ad.doubleclick.net/jump/usmf.inv.investing/articles;pos=overlay;seg=default;src=;sz=1x3;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?" rel="nofollow" target="_blank"><img src="http://ad.doubleclick.net/ad/usmf.inv.investing/articles;pos=overlay;seg=default;src=;sz=1x3;sub=default;port=default;trades=default;reg=false;uid=0;etfticker=false;ret=default;mgr=default;funds=default;goldticker=false;bureau=health-care;ord_aband=default;series=default;buckettarget=default;swap=false;sessionCount=1;tenOrMoreSessions=false;type=269;adtags=growth,health-care,pharma,tech;tickers=INO,RHHBY,NVAX;tile=0;ord=62663609?" border="0" alt=""></a></noscript>


	

    

<script type="text/javascript" src="http://www.fool.com/marketing/resources/js/jquery.bpopup-0.4.0.js"></script>
<script src="/common/js/fool/cookie.js" type="text/javascript"></script>
<script src="/common/js/marketing/exitpop.js" type="text/javascript"></script>
<style>
    
#exitInterrupt {
	margin-top: 30px;
	width: 500px;
	background-color: #fff !important;
	padding: 20px;
	padding-top: 10px;
	z-index: 100001;
	display: none;
	border-radius: 8px;
	-moz-border-radius: 8px;
	-webkit-border-radius: 8px;
}

#exitInterrupt h2 {
	font-size: 150%;
	
	display: block;
	width: 90%;
	padding: 20px;
	padding-left: 0px;
	font-family: Arial,sans-serif;
	font-weight: bold;
}

#exitInterrupt p {
	font-size:130%;
	margin-bottom: 20px;
}

a#closeOverlay {
	background: url("//g.foolcdn.com/common/img/ico/close.png") no-repeat scroll left top transparent;
	height: 35px;
	overflow: hidden;
	position: absolute;
	right: -22px;
	text-align: right;
	text-indent: 999px;
	top: -15px;
	width: 35px;
	cursor: pointer;
}

a#continueButton {
	background: #480 url(http://h.foolcdn.com/tmfstatic/img/button_lightbackground.gif) repeat-x left 0px;
	border: 1px solid #24b31c;
	color:#167011;
	cursor:pointer;
	padding: 15px 100px;
	text-decoration:none;
	border-radius: 5px;
	font-weight: bold;
	font-size: 130%;
	margin-top: 20px;
}

.center {
	text-align:center;
}

#transcriptLink {
	text-decoration: underline;
	cursor: pointer;
}

.transcriptText {
	font-size: 80% !important;
	margin-top: 20px;
}
#exitInterruptPrivacyLink {
    font-size: 10px;
    float: right;
}
#exitInterrupt h4 {
    margin-bottom: 5px;
}

</style>
<div id="exitInterrupt">
	<a id="closeOverlay" class="popClose" rel="closeOverlay"></a>

	<h2>Special Offer for Savvy Investors Like You!</h2>

	<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut semper dui vitae molestie venenatis. Suspendisse.</p>
        
    <script src="http://j.foolcdn.com/common/js/Controls/Landing/Ecap_Facebook.min.js?v=83336a" type="text/javascript"></script>

<div id="" class="ecap  clearfix">
	<h4 id="TMFECapWidgetErrorDiv">Enter Email Address:</h4>

	
        
        <input type="hidden" name="campaignId" value="4061" />
		<input type="hidden" name="source" value="iapsittic0000001" />
		<input type="hidden" name="messageSuccess" value="Thanks for registering. This box will disappear in 2 seconds" />
		<input type="hidden" name="returnUrl" value="http%3a%2f%2fwww.fool.com%2finvesting%2fgeneral%2f2014%2f05%2f12%2fheres-what-you-need-to-know-about-inovio-pharmaceu.aspx" />
		<span class="ecapFields clearfix">


		
				<input id="emailAddress" name="emailAddress" type="text" class="ecapInput" maxlength="50" value="Email Address" />
		
				<input type="submit" name="ecapPromoToggle$ECap$btnSubmit" value="Click Here — It's Free!" id="ecapPromoToggle_ECap_btnSubmit" class="ecapButton">
			

	    </span>			

		

				

		<span class="ecapValidation"></span>		
	
</div>







    
    <br/><br/>
	<a id="exitInterruptPrivacyLink" class="ecapPrivacy" href="http://www.fool.com/help/index.htm?display=newuser03" target="_blank">Privacy / Legal Information</a>
</div>    
        
                <!-- control -->
            						
    	
	
	<script type="text/javascript" src="https://apis.google.com/js/plusone.js"></script>
    
        <!-- AddThis Welcome BEGIN -->
    <script type="text/javascript" src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-4fccc73f4f57fb0a"></script>
    <script type='text/javascript'>
        addthis.bar.initialize({
            'default': {
                "backgroundColor": "#E5EBF9",
                "buttonColor": "#efefef",
                "textColor": "#222222",
                "buttonTextColor": "#444444"
            }, rules: [
                {
                    "name": "Twitter returning",
                    "match": { "referringService": "twitter", "returning": true },
                    "message": "If you find this article interesting:",
                    "action": {
                        "type": "button",
                        "text": "Tweet it!",
                        "verb": "share",
                        "service": "twitter"
                    }
                },
                {
                    "name": "Twitter new",
                    "match": { "referringService": "twitter", "returning": false },
                    "message": "We're on Twitter! Follow us on Twitter for your daily dose of Foolishness.",
                    "action": {
                        "type": "button",
                        "text": "Follow @themotleyfool",
                        "verb": "follow",
                        "service": "twitter",
                        "id": "themotleyfool"
                    }
                },
                {
                    "name": "Facebook returning",
                    "match": { "referringService": "facebook", "returning": true },
                    "message": "If you enjoyed the article, consider sharing it!",
                    "action": {
                        "type": "button",
                        "text": "Share on Facebook",
                        "verb": "share",
                        "service": "facebook"
                    }
                },
                {
                    "name": "Facebook new",
                    "match": { "referringService": "facebook", "returning": false },
                    "message": "We’re on Facebook! Like The Motley Fool on Facebook for your daily dose of Foolishness.",
                    "action": {
                        "type": "button",
                        "text": "Like The Motley Fool",
                        "verb": "like",
                        "service": "facebook",
                        "id": "themotleyfool"
                    }
                },
                {
                    "name": "linkedin",
                    "match": { "referringService": "linkedin" },
                    "message": "If you enjoyed this article, share it",
                    "action": {
                        "type": "button",
                        "text": "on LinkedIn",
                        "verb": "share",
                        "service": "linkedin"
                    }
                },
                {
                    "name": "stumbleupon",
                    "match": { "referringService": "stumbleupon" },
                    "message": "If you enjoy this article, do us a favor:",
                    "action": {
                        "type": "button",
                        "text": "Post on StumbleUpon",
                        "verb": "share",
                        "service": "stumbleupon"
                    }
                }
            ]
        });
    </script>
    <!-- AddThis Welcome END -->
   

    <!-- AddThis Google Analytic Tracking BEGIN -->
    <script type="text/javascript">
        var addthis_config = {
            data_ga_property: 'UA-3262475-1',
            data_ga_social: true
        }; 
    </script>
    	
    <!-- AddThis Google Analytic Tracking END -->
    
    <!-- GA Remarketing Pixels -->
    <script type="text/javascript">
        /* <![CDATA[ */
        var google_conversion_id = 1069646824;
        var google_conversion_label = "Ua-NCL7h6QUQ6IeG_gM";
        var google_custom_params = {
            STOCK_tckr : ['INO','NVAX','RHHBY'],
            FIN_interest : 'INVEST',
        };
        var google_remarketing_only = true;
    /* ]]> */
    </script>

    <script type="text/javascript" src="//www.googleadservices.com/pagead/conversion.js"></script>

    <noscript>
        <div style="display:inline;">
            <img height="1" width="1" style="border-style:none;" alt="" src="//googleads.g.doubleclick.net/pagead/viewthroughconversion/1069646824/?value=0&amp;label=Ua-NCL7h6QUQ6IeG_gM&amp;guid=ON&amp;script=0"/>
        </div>
    </noscript> 
   		
    <img src="http://www.fool.com/tracking/vs/vs_track_ads.gif?ad_tags=growth;health-care;pharma;tech&rnd=164277320&log=1" />
    
    <script type="text/javascript">
        Fool.onContent(function() {
            if (typeof(window.infotronQueue) !== "undefined")
                window.infotronQueue.EndOfPage('articlePageView');
        });
    </script>


	
	<script type="text/javascript">
	    (function() {
	        var nc = document.createElement('script'); nc.type = 'text/javascript'; nc.async = true;
	        nc.src = 'http://scripts.verticalacuity.com/vat/mon/vtw.js';
	        var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(nc, s);
	    })();
	</script>

	<!-- START Parse.ly Include: Standard -->
	<div id="parsely-root" style="display: none">
	  <div id="parsely-cfg" data-parsely-site="fool.com"></div>
	</div>
	<script>
	    (function(s, p, d) {
	        var h=d.location.protocol, i=p+"-"+s,
	            e=d.getElementById(i), r=d.getElementById(p+"-root"),
	            u=h==="https:"?"d1z2jf7jlzjs58.cloudfront.net"
	                :"static."+p+".com";
	        if (e) return;
	        e = d.createElement(s); e.id = i; e.async = true;
	        e.src = h+"//"+u+"/p.js"; r.appendChild(e);
	    })("script", "parsely", document);
	</script>
	<!-- END Parse.ly Include -->

	<script data-main="http://j.foolcdn.com/js/main.js" src="http://h.foolcdn.com/tmfstatic/js/vendor/require.js" type="text/javascript"></script>

		
<div style="position:absolute;bottom:0;right:0;">
	<a href="http://at.atwola.com/adlink/3.0/5113.1/221794/0/-1/size=3x2;noperf=1;alias=93317647;kvmn=93317647;kvpg=www.fool.com%2finvesting%2fgeneral%2f2014%2f05%2f12%2fher;kvugc=0;grp=288470508;misc=288470508" target="_blank">
		<img src="http://at.atwola.com/adserv/3.0/5113.1/221794/0/-1/size=3x2;noperf=1;alias=93317647;kvmn=93317647;kvpg=www.fool.com%2finvesting%2fgeneral%2f2014%2f05%2f12%2fher;kvugc=0;grp=288470508;misc=288470508" width="3" height="2" border="0" alt="Advertisement" />
	</a>
</div>

        <script type="text/javascript">
            jQuery(window).load(function () {
                var pitcherAds = pitcherAds || PitcherAds();
                pitcherAds.OnDomReady();
            });
        </script>
	</body>

	
	
	
	
	<!-- Content Reminders -->




</html>
